var title_f7_31_7664="Boceprevir drug interactions";
var content_f7_31_7664=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F66181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F66181&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Major drug interactions with protease inhibitors for treatment of chronic hepatitis C virus (genotype 1)*: Boceprevir",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"3\" width=\"20%\">",
"     </colgroup>",
"     <colgroup width=\"40%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Interacting class",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sample agents",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management suggestions",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"4\">",
"        <strong>",
"         Boceprevir is partly metabolized by CYP3A4/5. Co-administration of drugs that are strong inducers of CYP3A are known to REDUCE boceprevir serum concentrations and should be avoided whenever possible.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anticonvulsants",
"       </td>",
"       <td>",
"        Carbamazepine",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , fosphenytoin, oxcarbazepine, pentobarbital, phenobarbital",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , phenytoin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , primidone",
"       </td>",
"       <td rowspan=\"3\">",
"        Reduced boceprevir serum concentrations. Risk of HCV resistance and treatment failure.",
"       </td>",
"       <td rowspan=\"3\">",
"        Co-administration of boceprevir with these agents is contraindicated or not recommended according to the US prescribing information for boceprevir and/or the interacting drug. Consider substituting non-interacting agents. Note that metabolic effects may persist for weeks following discontinuation of a strong inducer.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Anti-infectives",
"       </td>",
"       <td>",
"        Nafcillin, rifampin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , rifabutin, rifapentine, certain HIV antiretrovirals",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Other",
"       </td>",
"       <td>",
"        Bosentan, dexamethasone, St. John's wort",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td colspan=\"4\">",
"        <strong>",
"         Boceprevir is a potent inhibitor of CYP3A4/5. Boceprevir may increase systemic exposure of a large number of drugs dependent on CYP3A clearance. The following is NOT a complete list of all potential interactions. See Lexi-Interact&trade; program included with UpToDate to check for additional boceprevir interactions.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Analgesic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" rowspan=\"2\">",
"        Opioid",
"       </td>",
"       <td>",
"        Buprenorphine, methadone",
"       </td>",
"       <td>",
"        Variable effect reported (increased or decreased exposure).",
"       </td>",
"       <td rowspan=\"2\">",
"        Monitor opioid effect. No specific dose adjustment recommended.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fentanyl, oxycodone",
"       </td>",
"       <td>",
"        Increased opioid concentration and effects possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Anti-infectives",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antibiotics, macrolide",
"       </td>",
"       <td>",
"        Clarithromycin, erythromycin, telithromycin",
"       </td>",
"       <td>",
"        Increased serum concentrations of macrolide antibiotics. Risk of QTc prolongation and potential cardiotoxicity.",
"       </td>",
"       <td>",
"        Consider substituting a non-interacting antibiotic such as azithromycin.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antifungals, triazole (systemic)",
"       </td>",
"       <td>",
"        Itraconazole, ketoconazole, posaconazole, voriconazole",
"       </td>",
"       <td>",
"        Serum concentrations of boceprevir and azole anti-fungals may be elevated. Risk of QTc prolongation and potential cardiotoxicity.",
"       </td>",
"       <td>",
"        If concurrent treatment required, monitor for toxicity including QTc interval prolongation. Itraconazole and ketoconazole doses greater than 200 mg per day should be avoided.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-malarials",
"       </td>",
"       <td>",
"        Halofantrine, lumefantrine, quinine, quinidine",
"       </td>",
"       <td>",
"        Anti-malarial toxicity including cinchonism (quinine and quinidine), QTc prolongation and risk of cardiotoxicity.",
"       </td>",
"       <td>",
"        Avoid co-administration of boceprevir with these anti-malarial drugs if possible.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HIV antiretrovirals",
"        <sup>",
"         &loz;",
"        </sup>",
"       </td>",
"       <td>",
"        Protease inhibitors, non-nucleoside reverse transcriptase inhibitors and tenofovir",
"       </td>",
"       <td colspan=\"2\">",
"        <strong>",
"         Interactions between HIV antiretrovirals and boceprevir can result in viral resistance and therapeutic failure. These interactions are discussed separately. For additional information, refer to topic Treatment of hepatitis C virus infection in the HIV-infected patient. Early consultation with HIV/HCV infectious diseases specialist is recommended.",
"        </strong>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Antineoplastic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &nbsp;",
"       </td>",
"       <td>",
"        Docetaxel, crizotinib",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , doxorubicin, gefitinib, imatinib, paclitaxel, pazopanib, sunitinib",
"       </td>",
"       <td>",
"        Increased serum concentration of antineoplastic and risk of toxicity.",
"       </td>",
"       <td>",
"        Closely monitor antineoplastic effects and adjust dose as needed. Avoid crizotinib.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Cardiovascular",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anticoagulants, orally active",
"        <sup>",
"         &sect;",
"        </sup>",
"       </td>",
"       <td>",
"        Apixaban",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , dabigatran, rivaroxaban",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , warfarin",
"       </td>",
"       <td>",
"        <p>",
"         Boceprevir has the potential to increase the risk of bleeding when used with rivaroxaban or apixaban. A significant interaction with dabigatran is not anticipated. However, clinical data are unavailable.",
"        </p>",
"        Variable anticoagulant effects have been associated with co-administration of boceprevir and warfarin.",
"       </td>",
"       <td>",
"        <p>",
"         Concurrent treatment with rivaroxaban is contraindicated. According to the licensed product information in some countries, avoidance of apixaban or dose reduction is recommended. Avoid dabigatran in patients with renal insufficiency (CrCl &lt;30 mL/minute).",
"        </p>",
"        Warfarin may be preferred due to the availability of international normalized ratio (INR) monitoring.",
"        <sup>",
"         &sect;",
"        </sup>",
"        Close INR monitoring and warfarin dose adjustment may be needed until INR is stabilized.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antiarrhythmics",
"       </td>",
"       <td>",
"        Amiodarone, bepridil, digoxin, dronedarone, flecainide, lidocaine (systemic), propafenone, quinidine",
"       </td>",
"       <td>",
"        Elevated risk of cardiotoxicity including hypotension and arrhythmias.",
"       </td>",
"       <td>",
"        Close monitoring of antiarrhythmic effects suggested, including serum concentrations, if available. Dose alteration of antiarrhythmic may be necessary. Initiate digoxin at lowest dose with titration according to digoxin serum concentrations.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Calcium channel blockers (CCB) dihydropyridine",
"       </td>",
"       <td>",
"        Amlodipine, felodipine, isradipine, nicardipine, nifedipine, nimodipine, nisoldipine",
"       </td>",
"       <td>",
"        More pronounced blood pressure lowering and/or cardiac effects due to elevated CCB concentration.",
"       </td>",
"       <td>",
"        If concurrent use is necessary, monitor for exaggerated CCB effects and adjust CCB dose as needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        HMG-CoA reductase inhibitors (\"statins\")",
"       </td>",
"       <td>",
"        Atorvastatin, lovastatin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , simvastatin",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Increased statin concentrations and elevated risk of myopathy.",
"       </td>",
"       <td>",
"        Concurrent treatment with lovastatin or simvastatin is contraindicated. Limit daily dose of atorvastatin to 20 mg with boceprevir. Pravastatin and fluvastatin are less likely to interact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Gastrointestinal",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antiemetic",
"       </td>",
"       <td>",
"        Aprepitant, fosaprepitant",
"       </td>",
"       <td>",
"        Increased antiemetic exposure.",
"       </td>",
"       <td>",
"        Monitor effect. No specific dose adjustment available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        GI motility agent",
"       </td>",
"       <td>",
"        Cisapride",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , domperidone",
"       </td>",
"       <td>",
"        Increased QTc prolongation and risk of cardiotoxicity.",
"       </td>",
"       <td>",
"        Concurrent treatment with cisapride is contraindicated. Monitor domperidone effect.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Glucocorticoids and anti-gout",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucocorticoids (systemic)",
"       </td>",
"       <td>",
"        Methylprednisolone, dexamethasone",
"       </td>",
"       <td>",
"        Increased methylprednisolone exposure. Dexamethasone may decrease boceprevir efficacy (see strong inducers, above).",
"       </td>",
"       <td>",
"        Monitor methylprednisolone for increased effect. No specific dose adjustment available. For dexamethasone recommendation, see strong inducers, above.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Glucocorticoids (inhaled or nasal)",
"       </td>",
"       <td>",
"        Budesonide, fluticasone",
"       </td>",
"       <td>",
"        Increased systemic exposure of inhaled/intranasal glucocorticoids.",
"       </td>",
"       <td>",
"        Avoid concurrent use with inhaled/intranasal budesonide or fluticasone. Beclomethasone and triamcinolone are less likely to interact. See interaction for long-acting beta agonist, salmeterol, below.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Anti-gout",
"       </td>",
"       <td>",
"        Colchicine",
"       </td>",
"       <td>",
"        Increased risk of colchicine toxicity including severe diarrhea, nausea and vomiting.",
"       </td>",
"       <td>",
"        For patients with normal renal/hepatic function the following colchicine dose reductions are suggested:",
"        <br/>",
"        <ul>",
"         <li>",
"          Acute gout: 0.6 mg once followed by 0.3 mg one hour later. Do not repeat before 72 hours.",
"         </li>",
"         <li>",
"          Gout prophylaxis: reduce dose by 50 percent; double interval",
"         </li>",
"         <li>",
"          Familial Mediterranean fever: maximum daily dose 0.6 mg",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Immunosuppressants",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        <p>",
"         Calcineurin inhibitors",
"        </p>",
"        mTOR kinase inhibitors",
"       </td>",
"       <td>",
"        Cyclosporine",
"        <sup>",
"         [1]",
"        </sup>",
"        , tacrolimus",
"        <sup>",
"         [1]",
"        </sup>",
"        , everolimus, sirolimus, temsirolimus",
"       </td>",
"       <td>",
"        Significantly elevated serum concentrations of calcineurin inhibitors and mTOR kinase inhibitors which could lead to renal failure, cardiotoxicity, or other serious or life-threatening toxicity.",
"       </td>",
"       <td>",
"        Closely monitor immunosuppressant serum concentrations for signs of toxicity (eg, nephrotoxicity). Significant immunosuppressant dosage reductions may be needed. Numerous drugs taken by transplant recipients can interact with boceprevir. Drug therapy should be managed by transplant specialists with expertise in pharmacokinetic-based dose adjustment and management of high-risk drug interactions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Pulmonary arterial hypertension and urologic agents",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Phosphodiesterase-5 inhibitors (PDE-5)",
"       </td>",
"       <td>",
"        Sildenafil",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , tadalafil",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , vardenafil",
"       </td>",
"       <td>",
"        Increased risk of hypotension, syncope, visual changes, and priapism.",
"       </td>",
"       <td>",
"        Concurrent use of boceprevir with PDE-5 inhibitors for treatment of pulmonary arterial hypertension is contraindicated. For treatment of erectile dysfunction, dose limits are suggested:",
"        <br/>",
"        <ul>",
"         <li>",
"          Limit sildenafil to single 25 mg dose per 48 hours",
"         </li>",
"         <li>",
"          Limit tadalafil to single 10 mg dose per 72 hours",
"         </li>",
"         <li>",
"          Limit vardenafil to single 2.5 mg dose per 24 hours",
"         </li>",
"        </ul>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Alpha-1 antagonists",
"       </td>",
"       <td>",
"        Alfuzosin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , silodosin",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , tamsulosin",
"       </td>",
"       <td>",
"        Increased risk of hypotension, syncope.",
"       </td>",
"       <td>",
"        Concurrent use of alpha-1 antagonists with boceprevir is contraindicated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Endothelin antagonist",
"       </td>",
"       <td>",
"        Bosentan",
"       </td>",
"       <td>",
"        Toxicities due to elevated bosentan exposure may include edema, hypotension, syncope, hematologic and hepatic abnormalities. In addition, bosentan may decrease boceprevir exposure.",
"       </td>",
"       <td>",
"        Bosentan interacts with numerous drugs. Consider alternate non-interacting therapy. Also see CYP3A4 strong inducers section \"other\", above.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Psychiatry, sedatives and hypnotics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Antidepressants",
"       </td>",
"       <td>",
"        Buspirone, citalopram, desipramine, escitalopram, mirtazapine, nefazodone, trazodone, venlafaxine",
"       </td>",
"       <td>",
"        Increased antidepressant exposure possible.",
"       </td>",
"       <td>",
"        Dose alteration may be needed, but no specific guidance is available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Benzodiazepines",
"       </td>",
"       <td>",
"        Alprazolam, clonazepam, diazepam, midazolam (oral",
"        <sup>",
"         &Delta;",
"        </sup>",
"        &gt; parenteral), triazolam",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Increased benzodiazepine exposure. Prolonged or excessive sedation.",
"       </td>",
"       <td>",
"        Oral midazolam and triazolam are contraindicated with boceprevir. Dose reduction of other benzodiazepines listed may be needed. Consider substituting a non-interacting benzodiazepine such as lorazepam, oxazepam, or temazepam.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Hypnotics",
"       </td>",
"       <td>",
"        Eszopiclone, zolpidem, zopiclone",
"       </td>",
"       <td>",
"        Increased hypnotic exposure possible.",
"       </td>",
"       <td>",
"        Dose alteration may be needed, but no specific guidance is available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Neuroleptics (antipsychotics)",
"       </td>",
"       <td>",
"        Aripiprazole, haloperidol, iloperidone, pimozide",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , quetiapine",
"       </td>",
"       <td>",
"        QTc prolongation and elevated risk of cardiotoxicity.",
"       </td>",
"       <td>",
"        Concurrent treatment with pimozide is contraindicated. A 50 percent dose reduction with iloperidone is suggested. Dose reduction of other interacting neuroleptics may be needed, but no specific recommendation is available.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Contraception",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Estrogen/progestogen hormonal contraception",
"       </td>",
"       <td>",
"        Ethinyl estradiol, mestranol, desogestrel, dienogest, drospirenone",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , ethynodiol diacetate, etonogestrel, levonorgestrel, medroxyprogesterone, norelgestromin, norethindrone, norgestimate, norgestrel",
"       </td>",
"       <td>",
"        Boceprevir can decrease the serum concentrations of ethinyl estradiol and alter the serum concentrations of progestogens causing failure of hormonal contraception.",
"       </td>",
"       <td>",
"        Women of child bearing potential should use two effective NON-hormonal methods of birth control. This is particularly important because ribavirin is teratogenic. In addition, drospirenone is contraindicated with boceprevir due to risk of hyperkalemia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"4\">",
"        Other",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Long-acting beta-agonist (inhaled)",
"       </td>",
"       <td>",
"        Salmeterol",
"       </td>",
"       <td>",
"        Increased systemic exposure to salmeterol. Increased risk of tachycardia and other adverse cardiovascular effects.",
"       </td>",
"       <td>",
"        Avoid inhaled salmeterol with boceprevir. Formoterol may be less likely to interact.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Ergot derivatives",
"       </td>",
"       <td>",
"        Dihydroergotamine",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , ergotamine",
"        <sup>",
"         &Delta;",
"        </sup>",
"        , methylergonovine",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Increased risk of ergotism characterized by peripheral vasospasm and ischemia.",
"       </td>",
"       <td rowspan=\"2\">",
"        Combination of these agents with boceprevir is contraindicated. Consider non-interacting alternate.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        Vasopressin receptor antagonist",
"       </td>",
"       <td>",
"        Conivaptan",
"        <sup>",
"         &Delta;",
"        </sup>",
"       </td>",
"       <td>",
"        Elevated serum concentration of conivaptan.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CYP: cytochrome P450; P-gp: membrane P-glycoprotein multidrug resistance transporter; HCV: hepatitis C virus (genotype 1); CCB: calcium channel blocker; mTOR inhibitor: mammalian target of rapamycin inhibitor.",
"     <br>",
"      * For information concerning specific interaction effects, see Lexi-Interact&trade; drug interactions application included with UpToDate.",
"      <br>",
"       &Delta;",
"       <strong>",
"        Co-administration of boceprevir with these agents is contraindicated or not recommended according to the US prescribing information for boceprevir and/or the interacting drug.",
"       </strong>",
"       <br>",
"        <font class=\"lozenge\">",
"         &loz;",
"        </font>",
"        Treatment of HCV in HIV infected patient is discussed elsewhere. For additional information, refer to topic Treatment of hepatitis C virus infection in the HIV-infected patient.",
"        <br>",
"         &sect; For additional information on interactions of novel oral anticoagulants, refer to topic Anticoagulants other than heparin and warfarin.",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Victrelis&trade; (boceprevir) US prescribing information, available at: file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ae879ebe-b620-4829-b6f8-74b58da1c771.",
"      </li>",
"      <li>",
"       Lexicomp Online. Copyright &copy; 1978-2013 Lexicomp, Inc. All Rights Reserved.",
"      </li>",
"     </ol>",
"     <br/>",
"     Additional references:",
"     <br/>",
"     <ol>",
"      <li>",
"       Hulskotte E, Gupta S, Xuan F et al. Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers. Hepatology 2012; 56(5):1622.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7664=[""].join("\n");
var outline_f7_31_7664=null;
var title_f7_31_7665="Lacidipine: International drug information";
var content_f7_31_7665=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Lacidipine: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F1979201\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Aponil (IT);",
"     </li>",
"     <li>",
"      Caldine (FR);",
"     </li>",
"     <li>",
"      Lacimen (ES);",
"     </li>",
"     <li>",
"      Lacipil (AR, BR, CZ, ES, HR, HU, IT, MX, PT);",
"     </li>",
"     <li>",
"      Lacirex (IT);",
"     </li>",
"     <li>",
"      Midotens (AR, BR, DK);",
"     </li>",
"     <li>",
"      Motens (BE, CH, DE, ES, GB, LU, NL);",
"     </li>",
"     <li>",
"      Tens (PT);",
"     </li>",
"     <li>",
"      Viapres (IT)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1979196\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Calcium Channel Blocker",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1979199\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of hypertension",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1979195\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adults: Oral: Initial: 2 mg as a single daily dose, preferably in the morning; may increase after 3-4 weeks to 4 mg/day; maximum dose: 6 mg/day",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1979198\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet: 2 mg, 4 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10402 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.97.94.19-A044F949FA-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7665=[""].join("\n");
var outline_f7_31_7665=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979201\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979196\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979199\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979195\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821108\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1979198\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10402\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10402|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_31_7666="Patient information: Idiopathic pulmonary fibrosis (The Basics)";
var content_f7_31_7666=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?19/9/19603\">",
"         Patient information: Lung transplant (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?25/21/25939\">",
"         Patient information: Medical care during advanced illness (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?36/16/37121\">",
"         Patient information: What are clinical trials? (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?27/34/28195\">",
"         Patient information: Chronic cough in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/50/28450\">",
"         Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Idiopathic pulmonary fibrosis (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/idiopathic-pulmonary-fibrosis-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10324911\">",
"      <span class=\"h1\">",
"       What is idiopathic pulmonary fibrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Idiopathic pulmonary fibrosis (also called &ldquo;IPF&rdquo;) is a lung disease that makes it hard to breathe. It damages the air sacs that send oxygen to the blood. This damage causes scars in the lungs. These changes make people with IPF cough and get short of breath. &nbsp;",
"     </p>",
"     <p>",
"      People who get IPF are usually older than 40. It is a very serious illness that cannot be cured and gets worse over time. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10324928\">",
"      <span class=\"h1\">",
"       Why did I get idiopathic pulmonary fibrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors do not know exactly how IPF starts. The risk of IPF is greater for people who:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Smoke or used to smoke",
"       </li>",
"       <li>",
"        Have breathed in a lot of toxic chemicals or pollution",
"       </li>",
"       <li>",
"        Have breathed in tiny pieces of material, such as certain types of dust, over a long time",
"       </li>",
"       <li>",
"        Have family members with pulmonary fibrosis",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10324945\">",
"      <span class=\"h1\">",
"       What are the symptoms of idiopathic pulmonary fibrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;IPF can start very slowly, so it might not cause any symptoms at first. When it does, symptoms can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Shortness of breath during exercise",
"       </li>",
"       <li>",
"        Dry cough",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10324960\">",
"      <span class=\"h1\">",
"       Are there tests for idiopathic pulmonary fibrosis?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. Doctors can do:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Blood tests to look for other types of lung disease. There is no blood test for IPF.",
"       </li>",
"       <li>",
"        Breathing tests to see how well your lungs are working. Breathing tests can show if your shortness of breath is caused by IPF or another disease such as emphysema. &nbsp;",
"       </li>",
"       <li>",
"        An imaging test called a &ldquo;CT scan.&rdquo; This test uses a special X-ray to create pictures of the inside of the body. It can show lung damage caused by IPF. &nbsp;",
"       </li>",
"       <li>",
"        If the doctor is not sure you have IPF after the CT scan, he or she might do a lung biopsy. In this test, a doctor does surgery to take a small sample of tissue from your lung. Another doctor looks at the sample under a microscope for signs of IPF.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10324975\">",
"      <span class=\"h1\">",
"       How is idiopathic pulmonary fibrosis treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;There is no treatment to cure IPF. It usually gets worse slowly. But doctors can treat some of the symptoms. These treatments can include:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Quitting smoking &ndash; If you smoke cigarettes, the most important thing you can do is STOP SMOKING.",
"       </li>",
"       <li>",
"        Oxygen &ndash; As IPF gets worse, some people need to breathe oxygen from a tank they carry with them.",
"       </li>",
"       <li>",
"        Pulmonary rehab&nbsp;&ndash; In pulmonary rehab, people learn exercises and ways to breathe that can help with IPF symptoms.",
"       </li>",
"       <li>",
"        Treatment for acid reflux - Acid reflux is when the acid that is normally in your stomach backs up into your esophagus. The esophagus is the tube that carries food from your mouth to your stomach. Acid reflux from the esophagus can add to the lung scarring from IPF. People who have acid reflux might need medicine to stop the acid reflux from making IPF worse.",
"       </li>",
"       <li>",
"        Medicine - No medicine has been shown to slow lung damage, but new medicines might be available soon.",
"       </li>",
"       <li>",
"        Clinical trials &ndash; Research studies of new treatments, such as medicines, that might help people with IPF",
"       </li>",
"       <li>",
"        Lung transplant &ndash; This is surgery to replace 1 or both diseased lungs with healthy lungs. It is done only if a person with IPF meets certain conditions.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      IPF sometimes gets worse very quickly. If this happens, doctors can try giving antibiotics and steroid medicines. (The steroid medicine is not the same as the steroids athletes take to build muscle.)",
"     </p>",
"     <p>",
"      People with IPF can get the flu shot and pneumonia vaccine. The flu and pneumonia can be very hard on the lungs. If you have IPF, your doctor might tell you to get these shots. &nbsp;",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10324990\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=see_link\">",
"       Patient information: What are clinical trials? (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=see_link\">",
"       Patient information: Medical care during advanced illness (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19603?source=see_link\">",
"       Patient information: Lung transplant (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=see_link\">",
"       Patient information: Chronic cough in adults (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/31/7666?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83031 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.195.65.248-1F43DE5731-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7666=[""].join("\n");
var outline_f7_31_7666=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10324911\">",
"      What is idiopathic pulmonary fibrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10324928\">",
"      Why did I get idiopathic pulmonary fibrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10324945\">",
"      What are the symptoms of idiopathic pulmonary fibrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10324960\">",
"      Are there tests for idiopathic pulmonary fibrosis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10324975\">",
"      How is idiopathic pulmonary fibrosis treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10324990\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/34/28195?source=related_link\">",
"      Patient information: Chronic cough in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/9/19603?source=related_link\">",
"      Patient information: Lung transplant (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/21/25939?source=related_link\">",
"      Patient information: Medical care during advanced illness (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?27/50/28450?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?36/16/37121?source=related_link\">",
"      Patient information: What are clinical trials? (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_31_7667="Foot fasciotomy";
var content_f7_31_7667=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F67034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F67034&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Fasciotomy of the foot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Two dorsal longitudinal incisions are made to access the foot compartments. The incisions are positioned medial to the second metatarsal shaft and lateral to the fourth metatarsal shaft. Each of the four sub-compartments of the interosseous compartment (turquoise) are opened between the metatarsal bones through the dorsal incisions. The calcaneal compartment (purple), which lies beneath the metatarsals, is opened directly. The lateral compartment (green) is decompressed through the lateral dorsal incision. The medial compartment (red) may be accessed by dissecting medial to the second metatarsal. Alternatively, the medial compartment can be accessed through another incision along the medial foot, immediately posterior to the first metatarsal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7667=[""].join("\n");
var outline_f7_31_7667=null;
var title_f7_31_7668="MRI of normal fetal bowel";
var content_f7_31_7668=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F66951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F66951&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 572px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance images of normal fetal bowel",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 552px; height: 354px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Normal fetal bowel at 24 weeks of gestation.",
"    <br>",
"     (A) T2w coronal image shows high signal fluid filled loops of bowel throughout the abdomen. Minimal low signal meconium can be seen in the pelvis.",
"     <br>",
"      (B) T1w coronal image better demonstrates high signal meconium filling the rectosigmoid and descending colon.",
"      <div class=\"footnotes\">",
"      </div>",
"      <div class=\"reference\">",
"       Courtesy of Dorothy I Bulas, MD.",
"      </div>",
"     </br>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7668=[""].join("\n");
var outline_f7_31_7668=null;
var title_f7_31_7669="Lung transplant rejection";
var content_f7_31_7669=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F51639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F51639&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Chronic lung transplant rejection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 239px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Peribronchiolar fibrosis in chronic lung transplant rejection. Photomicrograph demonstrating fibrosis around the lumen of a small airway.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of L Kobzik, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7669=[""].join("\n");
var outline_f7_31_7669=null;
var title_f7_31_7670="Primary lymphoma bone";
var content_f7_31_7670=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F67828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F67828&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Primary lymphoma of bone",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 324px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Histologic evaluation of a femoral resection in a case of diffuse large B cell lymphoma involving the bone. The photomicrograph demonstrates an infiltration of large pleomorphic cells, many of which contain highly convoluted, polylobated nuclear membranes with smudged chromatin and one to two inconspicuous nucleoli (\"floret cells,\" black arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Kindly provided by Julia M. Braza, MD, MS, German Pihan, MD, and Rajan Mariappan, MD, Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7670=[""].join("\n");
var outline_f7_31_7670=null;
var title_f7_31_7671="Sleep apnea and other causes of impaired sleep in older adults";
var content_f7_31_7671=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Sleep apnea and other causes of impaired sleep in older adults",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7671/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7671/contributors\">",
"     Steven H Feinsilver, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7671/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7671/contributors\">",
"     Robert C Basner, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7671/contributors\">",
"     Kenneth E Schmader, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7671/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7671/contributors\">",
"     April F Eichler, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/31/7671/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 17, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep-related complaints are common among older adults (ie, adults &gt;65 years old). It is often difficult to distinguish whether the impaired sleep that leads to such complaints is a consequence of normal aging or a disease process, such as a primary sleep disorder or a medical illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The causes of impaired sleep in older adults are reviewed here, with a focus on sleep apnea.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     THE EFFECTS OF NORMAL AGING ON SLEEP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep-related changes are a normal consequence of aging (",
"    <a class=\"graphic graphic_table graphicRef57544 \" href=\"UTD.htm?2/52/2891\">",
"     table 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Phase advance: Sleep during the early morning hours is reduced and peak sleepiness occurs earlier in the evening [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/2,3\">",
"       2,3",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sleep efficiency: The ratio of time asleep to time in bed declines, largely due to more nocturnal awakenings [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Sleep time: Total time spent asleep decreases, although the reduction in nocturnal sleep may be partially compensated by increased daytime napping [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/4\">",
"       4",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Daytime sleep latency: The time required to fall asleep during the day is significantly reduced in older adults compared with younger individuals, implying greater daytime somnolence with aging",
"     </li>",
"     <li>",
"      Nocturnal sleep latency: The time required to fall asleep at night is slightly increased or unchanged [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The pattern of sleep stages (ie, sleep architecture) also changes as individuals age. Specifically, the time until the first rapid eye movement (REM) period (ie, REM latency) shortens, the percentage of time spent in REM sleep decreases modestly, and slow wave sleep decreases from around 20 percent in the normal young adult to less than 10 percent in a 70 year-old [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/4\">",
"     4",
"    </a>",
"    ]. The stages and architecture of normal sleep are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=see_link\">",
"     \"Stages and architecture of normal sleep\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been speculated that the decrease in the percentage of slow wave sleep may be an artifact of measurement rather than a true decline in slow wave sleep. This is based upon two observations: the decrease in slow wave sleep is primarily due to a decline in the amplitude of electroencephalographic (EEG) activity, rather than a change in the frequency of EEG activity, and the smaller amplitude of EEG activity could reflect the increased electrical resistance across the scalp and skull that occurs with age. To address this concern, it has been proposed that the amplitude used to identify slow waves be reduced in older adults, but no consensus has been reached.",
"   </p>",
"   <p>",
"    The overall effect of these changes is that older adults tend to complain of difficulty maintaining sleep, more so than difficulty initiating sleep. As the time spent asleep at night decreases, there is increased daytime sleepiness, difficulty maintaining wakefulness, and a propensity for napping. Patients whose complaints are mild do not require any diagnostic testing or treatment. However, if the complaints seem out of proportion to normal aging (ie, are affecting basic activities of daily living or cognitive functioning) or there are other symptoms or signs of a primary sleep disorder, diagnostic testing is warranted to look for coexisting sleep disorders that require treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5201840\">",
"    <span class=\"h1\">",
"     OTHER CAUSES OF SLEEP IMPAIRMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are numerous causes of impaired sleep in older adults, other than normal aging.",
"   </p>",
"   <p>",
"    Lifestyle changes that accompany retirement, illness, or debilitation frequently contribute to poor habits that impair sleep (ie, poor sleep hygiene) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/5\">",
"     5",
"    </a>",
"    ]. Examples include spending long periods of time in bed, having an irregular sleep schedule, trying to force sleep, drinking caffeinated beverages or alcohol near bedtime (eg, late afternoon and evening), smoking or other nicotine intake particularly during the evening, stimuli in the bedroom environment (eg, ambient light, television, or radio), persistent concerns or worries at bedtime, lack of exercise, and frequent daytime naps (especially those that are longer than 20 to 30 minutes or occur late in the day).",
"   </p>",
"   <p>",
"    Many medical and psychiatric illnesses that are common in older adults are associated with poor sleep [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/6\">",
"     6",
"    </a>",
"    ]. Examples include cardiovascular disease, chronic pulmonary disease, arthritis, dementia, depression, anxiety, and nocturia. Any condition associated with chronic pain is likely to disturb sleep and provoke nocturnal awakenings. Anemia and chronic renal failure are risk factors for restless legs syndrome and periodic leg movements of sleep, resulting in poor sleep maintenance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Medications may also contribute to poor sleep. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=see_link\">",
"     \"Cheyne-Stokes breathing and obstructive sleep apnea in heart failure\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22150?source=see_link\">",
"     \"Sleep-disordered breathing in COPD\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=see_link\">",
"     \"Clinical manifestations and diagnosis of depression\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=see_link&amp;anchor=H15544430#H15544430\">",
"     \"Evaluation of chronic pain in adults\", section on 'Pain impact'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=see_link\">",
"     \"Restless legs syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary sleep disorders tend to be more common among older adults than younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/9\">",
"     9",
"    </a>",
"    ]. This is particularly true of sleep apnea, which is the focus of the remainder of this topic review.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SLEEP APNEA IN OLDER ADULTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Sleep apnea is a disorder characterized by apneas and hypopneas during sleep. It collectively describes both obstructive sleep apnea (OSA, in which apneas and hypopneas are due to repetitive collapse of the upper airway) and central sleep apnea (CSA, in which apneas and hypopneas occur in the absence of upper airway collapse). OSA is more common than CSA in all age groups. Herein, we use the term, sleep apnea, when describing OSA and CSA collectively or when describing studies that did not distinguish the type of sleep apnea. Otherwise, we refer to OSA or CSA specifically. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link\">",
"     \"Sleep related breathing disorders in adults: Definitions\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It has been suggested that sleep apnea in older adults may be a different disorder than sleep apnea in younger adults, with unique mechanisms due to structural changes in the upper airway and increases in pharyngeal resistance. While this possibility has not been definitively excluded, most of the evidence indicates that sleep apnea manifests the same way in older and younger adults. This was illustrated by an observational study of 389 consecutive patients who were diagnosed with sleep apnea; patients &ge;65 years old did not differ in terms of their disease severity, their polysomnographic data, or the therapeutic implications of their diagnostic study, compared with patients &lt;65 years old [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2139733\">",
"    <span class=\"h2\">",
"     Prevalence",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of sleep apnea in older adults appears to increase among older individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/11-14\">",
"     11-14",
"    </a>",
"    ] and less healthy individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/15\">",
"     15",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The notion that the prevalence of sleep apnea increases among older individuals was illustrated by an observational study of 105 healthy, nonobese adults who were stratified by age [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/11\">",
"       11",
"      </a>",
"      ]. Sleep apnea was defined as a respiratory disturbance index (RDI) &ge;5 events per hour of sleep. The study detected sleep apnea in 3 percent of 60 year-old individuals, 33 percent of 70 year-old individuals, and 40 percent of 80 year-old individuals. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H13#H13\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Respiratory disturbance index'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The belief that the prevalence of sleep apnea increases among less healthy individuals was demonstrated another observational study that used an apnea index (AI) &ge;10 events per hour of sleep to define sleep apnea [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/15\">",
"       15",
"      </a>",
"      ]. The prevalence of sleep apnea was 10 percent among independently living older adults, 21 percent among medical ward patients, and 26 percent among nursing home patients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=see_link&amp;anchor=H11#H11\">",
"       \"Sleep related breathing disorders in adults: Definitions\", section on 'Apnea index'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An important potential limitation of these observations is that the patient population consisted of individuals referred to a sleep center for evaluation; therefore, the applicability of these results to the general population is uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2610233\">",
"    <span class=\"h2\">",
"     Natural history",
"    </span>",
"    &nbsp;&mdash;&nbsp;Untreated severe sleep apnea has been associated with mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/16-18\">",
"     16-18",
"    </a>",
"    ] and multiple morbidities [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/19-23\">",
"     19-23",
"    </a>",
"    ] in adult populations that are heterogeneous with respect to age. These associations have not been as well studied in older adults and, often, the best evidence related to older adults is from the subgroup analyses of studies that included adults of all ages. This section focuses on the natural history of untreated sleep apnea specifically in older patients. The natural history of untreated sleep apnea in adults of all ages is described elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=see_link&amp;anchor=H12#H12\">",
"     \"Overview of obstructive sleep apnea in adults\", section on 'Natural history'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mortality: Untreated severe sleep apnea has not been associated with increased mortality in older patients, even though the association has been demonstrated in studies that evaluated adults of all ages [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/16-18\">",
"     16-18",
"    </a>",
"    ]. As an example, a prospective cohort study followed 6441 adults for an average of eight years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/16\">",
"     16",
"    </a>",
"    ]. Among all adults, untreated severe sleep apnea (defined as an apnea hypopnea index [AHI] &gt;30 events per hour of sleep) was associated with increased mortality compared with no sleep apnea (defined as an AHI &lt;5 events per hour of sleep). However, in the subgroup of 110 adults who were &gt;70 years-old, untreated severe sleep apnea was not associated with increased mortality compared with no sleep apnea (relative risk 1.27, 95% CI 0.86-1.86 among men; relative risk 1.14, 95% CI 0.65-2.01 among women) although there were too few events in the subgroup to definitively exclude or confirm a mortality effect.",
"   </p>",
"   <p>",
"    Stroke: Untreated severe sleep apnea has been associated with risk for an ischemic stroke in older adults. In a prospective cohort study of 400 adults aged 70 to 100 years who were followed for six years, an ischemic stroke occurred in 20 patients (5 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with untreated severe sleep apnea (defined as AHI &ge;30 events per hour of sleep) had an increased risk of developing an ischemic stroke (adjusted hazard ratio 2.52, 95% CI 1.04-6.01) compared with those who did not have sleep apnea.",
"   </p>",
"   <p>",
"    Cognitive abnormalities: The potential relationship between sleep apnea and cognitive defects is important because both sleep apnea and dementia are highly prevalent among older adults. Numerous observational studies have found an association between sleep apnea and cognitive defects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/19,25-27\">",
"     19,25-27",
"    </a>",
"    ]. In one study, 298 women (mean age of 82 years) underwent polysomnography and then were followed prospectively for four years for the development of neurocognitive defects, as determined by cognitive testing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/19\">",
"     19",
"    </a>",
"    ]. Women with sleep apnea (defined as AHI &ge;15 events per hour of sleep) were more likely to develop mild cognitive defects or dementia than women with sleep apnea (45 versus 31 percent, adjusted odds ratio 1.85, 95% CI 1.11-3.08). However, conflicting studies exist [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hypertension: Untreated sleep apnea characterized by an oxyhemoglobin saturation &lt;90 percent for &ge;12 percent of the sleep time (and not by the AHI) was more closely associated with the prevalence of systemic hypertension in patients &gt;65 years old (adjusted odds ratio 1.44, 95% CI 1.03-2.00) than patients &lt;65 years old (adjusted odds ratio 1.26, 95% CI 0.89-1.78) in a cross-sectional study of 6132 adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/29\">",
"     29",
"    </a>",
"    ]. However, studies that have used the AHI alone to compare older adults with untreated severe sleep apnea to older adults without sleep apnea, have found that the strength of the association between sleep apnea and systemic hypertension diminishes with age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/29-31\">",
"     29-31",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Coronary artery disease: Untreated severe sleep apnea (defined as AHI &ge;30 events per hour of sleep) was associated with an increased risk of coronary artery disease (defined as myocardial infarction, revascularization procedure, or death due to coronary artery disease) in men 40 to 70 years old (adjusted hazard ratio 1.68, 95% CI 1.02-2.76), but not in older men or in women of any age in a prospective cohort study that followed 4422 adults for a median of almost nine years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/20\">",
"     20",
"    </a>",
"    ]. Other studies have been unable to confirm this association because there were too few events to allow stratification by age [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Heart failure: It is unclear whether untreated severe sleep apnea (defined as AHI &ge;30 events per hour of sleep) may also be associated with the development of heart failure in older patients with heart failure. In the prospective cohort study of 4422 adults described above, both men older and younger than 70 years with severe untreated sleep apnea exhibited a trend toward more incident heart failure than men of the same age who did not have sleep apnea (adjusted hazard ratio 1.58, 95% CI 0.93-2.66) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7671/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2139794\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathogenesis of sleep apnea is the same in older adults and younger adults. In patients with OSA, apneas and hypopneas are consequences of repetitive upper airway collapse, while in patients with CSA, apneas and hypopneas are consequences of either hyperventilation or hypoventilation. These mechanisms are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24454?source=see_link\">",
"     \"Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19140?source=see_link\">",
"     \"Central sleep apnea: Pathogenesis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2139764\">",
"    <span class=\"h2\">",
"     Clinical manifestations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical manifestations of sleep apnea in older adults are similar to those in younger adults. Excessive daytime sleepiness or fatigue is the most common finding, but patients may also exhibit poor concentration, inattention, morning headaches, or restless sleep. Patients with OSA generally snore loudly and frequently awake with a sensation of choking, gasping, or smothering. The symptoms and signs of sleep apnea are described in greater details separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H2#H2\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Clinical presentation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=see_link&amp;anchor=H26263960#H26263960\">",
"     \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\", section on 'Clinical presentation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2139824\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnostic evaluation of suspected sleep apnea is the same in older adults and younger adults, with polysomnography being the most definitive diagnostic test. An approach to diagnosing sleep apnea is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=see_link&amp;anchor=H7#H7\">",
"     \"Clinical presentation and diagnosis of obstructive sleep apnea in adults\", section on 'Indications for diagnostic testing'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=see_link&amp;anchor=H10#H10\">",
"     \"Central sleep apnea: Risk factors, clinical presentation, and diagnosis\", section on 'Diagnostic evaluation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of sleep apnea in older adults is similar to the management in younger adults. This includes the indications for treatment, behavior modification, selection of the sleep-apnea specific therapy (ie, positive airway pressure, oral appliance, surgery), and follow-up. This section describes the few differences that exist when managing an older adult with sleep apnea. The management of sleep apnea is described in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=see_link\">",
"     \"Management of obstructive sleep apnea in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=see_link\">",
"     \"Central sleep apnea: Treatment\"",
"    </a>",
"    .).",
"   </p>",
"   <p>",
"    Older adults tend to be more challenging to treat than younger patients several reasons. First, they experience nocturnal awakenings by virtue of age alone. Second, those being managed with positive airway pressure therapy may have difficulty achieving a good fit with either a nasal or face mask, especially if they are edentulous. Third, additional time is often needed to educate patients about positive airway pressure therapy, cleaning the device, and using the device. Fourth, some patients prefer an oral appliance over positive airway pressure, but oral appliances may not be an option for some patients because adequate dentition is required to anchor the oral appliance in position. Finally, comorbidities may prohibit a surgical approach in some patients.",
"   </p>",
"   <p>",
"    Avoiding all sedatives (including alcohol) is a particularly important aspect of managing sleep apnea in older adults. Sedatives decrease the respiratory drive, worsen upper airway dysfunction during sleep, and have been shown to dramatically worsen the severity of sleep apnea. Older adults tend to be more sensitive to these effects due to age-related changes in pharmacokinetics and pharmacodynamics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5201400\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Sleep-related complaints are common among older adults (ie, adults &gt;65 years old). It is often difficult to distinguish whether the impaired sleep that leads to such complaints is a consequence of normal aging or a disease process, such as a primary sleep disorder or a medical illness. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleep-related changes that are a normal consequence of aging include phase advance (ie, sleep during the early morning hours is reduced and peak sleepiness occurs earlier in the evening), decreased sleep efficiency, diminished total sleep time, and reduced daytime sleep latency. The overall effect of these changes is that older adults tend to complain of difficulty maintaining sleep. As the time spent asleep at night decreases, there is increased daytime sleepiness and napping. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'The effects of normal aging on sleep'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In contrast, causes of impaired sleep that are unrelated to normal aging include lifestyle changes (ie, poor sleep hygiene), medical illnesses, primary sleep disorders, and psychiatric illnesses. (See",
"      <a class=\"local\" href=\"#H5201840\">",
"       'Other causes of sleep impairment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Primary sleep disorders tend to be more common among older adults than younger adults. This is particularly true of sleep apnea, a disorder characterized by apneas and hypopneas during sleep. The prevalence of sleep apnea in older adults is substantial and appears to increase among older individuals and less healthy individuals. (See",
"      <a class=\"local\" href=\"#H2139733\">",
"       'Prevalence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Sleep apnea has been associated with stroke, mild cognitive defects, and dementia in older adults. It also appears to be associated with systemic hypertension if accompanied by significant hypoxemia. Sleep apnea has not been associated with mortality in older adults, as studies have had too few events to either exclude or confirm a mortality effect. (See",
"      <a class=\"local\" href=\"#H2610233\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The pathogenesis, clinical manifestations, diagnosis, and treatment of sleep apnea are essentially the same in older and younger adults. (See",
"      <a class=\"local\" href=\"#H2139794\">",
"       'Pathogenesis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2139764\">",
"       'Clinical manifestations'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H2139824\">",
"       'Diagnosis'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/1\">",
"      Ayalon L, Liu L, Ancoli-Israel S. Diagnosing and treating sleep disorders in the older adult. Med Clin North Am 2004; 88:737.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/2\">",
"      Feinsilver SH, Hertz G. Sleep in the elderly patient. Clin Chest Med 1993; 14:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/3\">",
"      Haimov I, Lavie P. Circadian characteristics of sleep propensity function in healthy elderly: a comparison with young adults. Sleep 1997; 20:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/4\">",
"      Ohayon MM, Carskadon MA, Guilleminault C, Vitiello MV. Meta-analysis of quantitative sleep parameters from childhood to old age in healthy individuals: developing normative sleep values across the human lifespan. Sleep 2004; 27:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/5\">",
"      Schnelle JF, Cruise PA, Alessi CA, et al. Sleep hygiene in physically dependent nursing home residents: behavioral and environmental intervention implications. Sleep 1998; 21:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/6\">",
"      Quan SF, Zee P. Evaluating the effects of medical disorders on sleep in the older patient. Geriatrics 2004; 59:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/7\">",
"      Hornyak M, Trenkwalder C. Restless legs syndrome and periodic limb movement disorder in the elderly. J Psychosom Res 2004; 56:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/8\">",
"      Barthlen GM. Sleep disorders. Obstructive sleep apnea syndrome, restless legs syndrome, and insomnia in geriatric patients. Geriatrics 2002; 57:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/9\">",
"      Jennum P, Riha RL. Epidemiology of sleep apnoea/hypopnoea syndrome and sleep-disordered breathing. Eur Respir J 2009; 33:907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/10\">",
"      L&eacute;vy P, P&eacute;pin JL, Malauzat D, et al. Is sleep apnea syndrome in the elderly a specific entity? Sleep 1996; 19:S29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/11\">",
"      Hoch, C, Reynolds, CF III, Monk, TH, et al. Comparison of sleep disordered breathing among healthy elderly in the seventh, eighth, and ninth decades of life. Sleep 1990; 13:502.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/12\">",
"      Viner S, Szalai JP, Hoffstein V. Are history and physical examination a good screening test for sleep apnea? Ann Intern Med 1991; 115:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/13\">",
"      Crocker BD, Olson LG, Saunders NA, et al. Estimation of the probability of disturbed breathing during sleep before a sleep study. Am Rev Respir Dis 1990; 142:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/14\">",
"      Flemons WW, Whitelaw WA, Brant R, Remmers JE. Likelihood ratios for a sleep apnea clinical prediction rule. Am J Respir Crit Care Med 1994; 150:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/15\">",
"      Ancoli-Israel S. Epidemiology of sleep disorders. Clin Geriatr Med 1989; 5:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/16\">",
"      Punjabi NM, Caffo BS, Goodwin JL, et al. Sleep-disordered breathing and mortality: a prospective cohort study. PLoS Med 2009; 6:e1000132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/17\">",
"      Marshall NS, Wong KK, Liu PY, et al. Sleep apnea as an independent risk factor for all-cause mortality: the Busselton Health Study. Sleep 2008; 31:1079.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/18\">",
"      Young T, Palta M, Dempsey J, et al. Burden of sleep apnea: rationale, design, and major findings of the Wisconsin Sleep Cohort study. WMJ 2009; 108:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/19\">",
"      Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA 2011; 306:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/20\">",
"      Gottlieb DJ, Yenokyan G, Newman AB, et al. Prospective study of obstructive sleep apnea and incident coronary heart disease and heart failure: the sleep heart health study. Circulation 2010; 122:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/21\">",
"      Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/american College Of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council On Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008; 118:1080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/22\">",
"      Redline S, Yenokyan G, Gottlieb DJ, et al. Obstructive sleep apnea-hypopnea and incident stroke: the sleep heart health study. Am J Respir Crit Care Med 2010; 182:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/23\">",
"      George CF. Sleep apnea, alertness, and motor vehicle crashes. Am J Respir Crit Care Med 2007; 176:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/24\">",
"      Munoz R, Duran-Cantolla J, Mart&iacute;nez-Vila E, et al. Severe sleep apnea and risk of ischemic stroke in the elderly. Stroke 2006; 37:2317.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/25\">",
"      Berry DT, Webb WB, Block AJ, et al. Nocturnal hypoxia and neuropsychological variables. J Clin Exp Neuropsychol 1986; 8:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/26\">",
"      Findley LJ, Barth JT, Powers DC, et al. Cognitive impairment in patients with obstructive sleep apnea and associated hypoxemia. Chest 1986; 90:686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/27\">",
"      Yesavage J, Bliwise D, Guilleminault C, et al. Preliminary communication: intellectual deficit and sleep-related respiratory disturbance in the elderly. Sleep 1985; 8:30.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/28\">",
"      Foley DJ, Masaki K, White L, et al. Sleep-disordered breathing and cognitive impairment in elderly Japanese-American men. Sleep 2003; 26:596.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/29\">",
"      Nieto FJ, Young TB, Lind BK, et al. Association of sleep-disordered breathing, sleep apnea, and hypertension in a large community-based study. Sleep Heart Health Study. JAMA 2000; 283:1829.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/30\">",
"      Bixler EO, Vgontzas AN, Lin HM, et al. Association of hypertension and sleep-disordered breathing. Arch Intern Med 2000; 160:2289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7671/abstract/31\">",
"      Grote L, Ploch T, Heitmann J, et al. Sleep-related breathing disorder is an independent risk factor for systemic hypertension. Am J Respir Crit Care Med 1999; 160:1875.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7692 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-118.97.94.19-18180375D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7671=[""].join("\n");
var outline_f7_31_7671=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5201400\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      THE EFFECTS OF NORMAL AGING ON SLEEP",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5201840\">",
"      OTHER CAUSES OF SLEEP IMPAIRMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SLEEP APNEA IN OLDER ADULTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2139733\">",
"      Prevalence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2610233\">",
"      Natural history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2139794\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2139764\">",
"      Clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2139824\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5201400\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/7692\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/7692|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/52/2891\" title=\"table 1\">",
"      Sleep patterns in elderly",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/44/19140?source=related_link\">",
"      Central sleep apnea: Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/29/44502?source=related_link\">",
"      Central sleep apnea: Risk factors, clinical presentation, and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/20/39239?source=related_link\">",
"      Central sleep apnea: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/43/8888?source=related_link\">",
"      Cheyne-Stokes breathing and obstructive sleep apnea in heart failure",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/13/11481?source=related_link\">",
"      Clinical manifestations and diagnosis of depression",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/40/41607?source=related_link\">",
"      Clinical presentation and diagnosis of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/22/40296?source=related_link\">",
"      Evaluation of chronic pain in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/48/2826?source=related_link\">",
"      Management of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/56/24454?source=related_link\">",
"      Mechanisms and anatomic sites of upper airway obstruction in obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/13/6359?source=related_link\">",
"      Overview of obstructive sleep apnea in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/50/32554?source=related_link\">",
"      Restless legs syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/59/15286?source=related_link\">",
"      Sleep related breathing disorders in adults: Definitions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/40/22150?source=related_link\">",
"      Sleep-disordered breathing in COPD",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/57/9109?source=related_link\">",
"      Stages and architecture of normal sleep",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_31_7672="Congenital toxoplasmosis: Treatment, outcome, and prevention";
var content_f7_31_7672=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital toxoplasmosis: Treatment, outcome, and prevention",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7672/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7672/contributors\">",
"     Nicholas G Guerina, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7672/contributors\">",
"     Jennifer Lee, MD, MS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7672/contributors\">",
"     Ruth Lynfield, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7672/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7672/contributors\">",
"     Sheldon L Kaplan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7672/contributors\">",
"     Leonard E Weisman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7672/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7672/contributors\">",
"     Mary M Torchia, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/31/7672/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 9, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H4829118\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <em>",
"     Toxoplasma gondii",
"    </em>",
"    is a ubiquitous protozoan parasite that infects animals and humans.",
"    <em>",
"     Toxoplasma",
"    </em>",
"    infection typically is asymptomatic in immunocompetent hosts. However, serious disease can occur, most frequently in the setting of immunosuppression or congenital infection. The fetus, newborn, and young infant with congenital",
"    <em>",
"     Toxoplasma",
"    </em>",
"    infection are at risk of infection-associated complications, particularly retinal disease that can occur into adulthood.",
"   </p>",
"   <p>",
"    The treatment, outcome, and prevention of congenital toxoplasmosis will be discussed here. The clinical features and diagnosis of congenital toxoplasmosis and acquired toxoplasmosis in pregnancy, immunocompetent hosts, and HIV-infected patients are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link\">",
"     \"Congenital toxoplasmosis: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link\">",
"     \"Toxoplasmosis and pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=see_link\">",
"     \"Toxoplasmosis in immunocompetent hosts\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=see_link\">",
"     \"Toxoplasmosis in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829752\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY OF UNTREATED DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of untreated symptomatic congenital toxoplasmosis was demonstrated in a case series of 156 patients from the 1940s, of whom 152 had overt neurologic or generalized manifestations of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/1\">",
"     1",
"    </a>",
"    ]. Mortality was 12 percent. The majority of patients developed intellectual disability (93 percent), seizures (81 percent),",
"    <span class=\"nowrap\">",
"     spasticity/palsies",
"    </span>",
"    (70 percent), and severely impaired vision (60 percent). Other sequelae included hydrocephalus or microcephaly (33 percent) and deafness (15 percent).",
"   </p>",
"   <p>",
"    Children with subclinical infection also may develop cognitive, motor, auditory, and visual defects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/2-5\">",
"     2-5",
"    </a>",
"    ], but it is not possible to predict the likelihood of these complications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/6\">",
"     6",
"    </a>",
"    ]. It has been shown, however, that severe sequelae may occur and new-onset chorioretinitis, in particular, may occur in up to 90 percent of untreated children with congenital",
"    <em>",
"     Toxoplasma",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829759\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829767\">",
"    <span class=\"h2\">",
"     Antiparasitic therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829774\">",
"    <span class=\"h3\">",
"     Indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;We recommend treatment with antiparasitic therapy for infants (&lt;12 months) in whom a diagnosis of congenital toxoplasmosis is confirmed or highly likely, including [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7\">",
"     7",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants diagnosed with congenital toxoplasmosis prenatally (whether or not their mothers received chemotherapy) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link&amp;anchor=H11#H11\">",
"       \"Toxoplasmosis and pregnancy\", section on 'Diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infants with suspected congenital toxoplasmosis who have confirmation serology or PCR performed by a reference laboratory (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link&amp;anchor=H11762879#H11762879\">",
"       \"Congenital toxoplasmosis: Clinical features and diagnosis\", section on 'Evaluation and diagnosis'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Infants with evidence of recent maternal",
"      <em>",
"       T. gondii",
"      </em>",
"      infection in conjunction with clinical findings compatible with congenital toxoplasmosis in the infant (chorioretinitis, intracranial calcifications,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hydrocephalus)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given the increased risk of late sequelae in untreated congenital toxoplasmosis, we also suggest antiparasitic treatment for asymptomatic infants with equivocal newborn serology, pending definitive diagnosis (which may take months) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/6\">",
"     6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link&amp;anchor=H1833316#H1833316\">",
"     \"Congenital toxoplasmosis: Clinical features and diagnosis\", section on 'Interpretation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829781\">",
"    <span class=\"h3\">",
"     Treatment regimen",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preferred antiparasitic regimen includes",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    plus",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    (or sulfamerazine or sulfamethazine) and folinic acid (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/6,8-11\">",
"     6,8-11",
"    </a>",
"    ]. Sulfamerazine and sulfamethazine are not available in the United States. The optimal doses and duration for these drugs are not established definitively and should be determined in consultation with specialists in pediatric infectious diseases.",
"   </p>",
"   <p>",
"    We suggest:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 50",
"      <span class=\"nowrap\">",
"       mg/dose)",
"      </span>",
"      once daily for two days; then 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 25",
"      <span class=\"nowrap\">",
"       mg/dose)",
"      </span>",
"      once daily for six months; then 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 25",
"      <span class=\"nowrap\">",
"       mg/dose)",
"      </span>",
"      every other day (ie, Monday, Wednesday, and Friday) to complete one year of therapy,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"       Sulfadiazine",
"      </a>",
"      100",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in two doses every day for one year,",
"      <strong>",
"       plus",
"      </strong>",
"     </li>",
"     <li>",
"      Folinic acid (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=see_link\">",
"       leucovorin",
"      </a>",
"      ) 10 mg three times per week during and for one week after",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      therapy",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For infants with clinical evidence of toxoplasmosis, combination therapy for one year is associated with decreased incidence of long-term complications and decreased incidence of new-onset ocular disease compared with no treatment or treatment for shorter periods [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/5,7,12-14\">",
"     5,7,12-14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6012724\">",
"     'Efficacy'",
"    </a>",
"    below.) One year of treatment is recommended by many experts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/6,9-11\">",
"     6,9-11",
"    </a>",
"    ]. However, in some centers, treatment is continued for two years.",
"   </p>",
"   <p>",
"    Glucocorticoids (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    0.5 mg twice per day) are added if cerebrospinal fluid (CSF) protein is &gt;1",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    or when active chorioretinitis threatens vision [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7\">",
"     7",
"    </a>",
"    ]. Glucocorticoids are continued until resolution of elevated CSF protein or active chorioretinitis that threatens vision. The benefit of adjunctive glucocorticoids has not been demonstrated in controlled trials; adverse effects have not been noted in cohort studies.",
"   </p>",
"   <p>",
"    The infant should be weighed weekly and the doses adjusted accordingly [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7\">",
"     7",
"    </a>",
"    ].",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     Pyrimethamine",
"    </a>",
"    should be temporarily withheld if the absolute neutrophil count (ANC) falls below 500",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    The dose of folinic acid may be increased as needed if the ANC falls below 1000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"   </p>",
"   <p>",
"    For infants who develop an allergy to",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    (20 to 30",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day divided in four doses) may be substituted [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/15\">",
"     15",
"    </a>",
"    ]. Skin exanthems (hives, allergic dermatitis) are the most common allergic reactions to sulfadiazine, but severe leucopenia rarely can occur; sulfadiazine-induced leucopenia should be considered in any infant who develops leucopenia unresponsive to increased folinic acid (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) dosing or temporary discontinuation of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    . (See",
"    <a class=\"local\" href=\"#H4829802\">",
"     'Therapeutic monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6013042\">",
"    <span class=\"h4\">",
"     Special considerations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Special considerations are necessary for children with renal insufficiency or glucose-6-phosphate-dehydrogenase (G6PD) deficiency and those taking anticonvulsant or antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7,16\">",
"     7,16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"       Sulfadiazine",
"      </a>",
"      is excreted in the kidney, and the dose may require adjustment for infants with renal insufficiency. (See",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"       \"Sulfadiazine: Pediatric drug information\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"       Sulfadiazine",
"      </a>",
"      may cause hemolysis in children with G6PD deficiency;",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"       clindamycin",
"      </a>",
"      may be substituted for sulfadiazine in children with G6PD deficiency. The combination of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      and clindamycin has been used to successfully treat toxoplasmic encephalitis in patients with AIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/15,17,18\">",
"       15,17,18",
"      </a>",
"      ], and the authors have used it without complications in a child with severe G6PD deficiency. The authors have also used pyrimethamine and clindamycin in several children who developed sulfadiazine allergy. However, high-dose pyrimethamine has been reported to cause hemolytic anemia in some patients with G6PD deficiency, and such patients should be monitored closely. Combination antiparasitic therapy is recommended for treating",
"      <em>",
"       Toxoplasma",
"      </em>",
"      infection, so in children not able to take either pyrimethamine or sulfadiazine, clindamycin plus an alternative agent should be selected in consultation with an infectious disease expert.",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"       Sulfadiazine",
"      </a>",
"      may prolong the half-life of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?32/19/33082?source=see_link\">",
"       phenytoin",
"      </a>",
"      (via interference with hepatic microsomal enzymes), and dosing adjustments may be necessary.",
"     </li>",
"     <li>",
"      Concomitant administration of",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?5/36/5706?source=see_link\">",
"       carbamazepine",
"      </a>",
"      ,",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?11/7/11383?source=see_link\">",
"       clonazepam",
"      </a>",
"      , or",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?26/55/27512?source=see_link\">",
"       zidovudine",
"      </a>",
"      may exacerbate bone marrow suppression and neutropenia.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6012724\">",
"    <span class=\"h3\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of postnatal antiparasitic therapy for congenital toxoplasmosis is unknown [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. There are no randomized trials of antiparasitic therapy versus placebo or no treatment. However,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    (alone or in combination with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    or",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/56/34688?source=see_link\">",
"     clindamycin",
"    </a>",
"    ) has been shown to be effective against",
"    <em>",
"     T. gondii",
"    </em>",
"    in vitro and in randomized trials in adults with acquired human",
"    <em>",
"     Toxoplasma",
"    </em>",
"    infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/15,16,21-23\">",
"     15,16,21-23",
"    </a>",
"    ]. It is synergistic with sulfadiazine.",
"   </p>",
"   <p>",
"    There is a general consensus that long-term combination therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    (plus folinic acid) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    (or sulfamerazine or sulfamethazine) is beneficial for infants with congenital toxoplasmosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/20\">",
"     20",
"    </a>",
"    ]. The consensus is based upon cohort studies demonstrating improved outcomes among treated infants compared with historical controls [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7,12-14\">",
"     7,12-14",
"    </a>",
"    ]. Among these, the National Collaborative Chicago-Based Congenital Toxoplasmosis Study (NCCCTS) has the longest duration of follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. The NCCCTS randomly assigned 120 infants with congenital toxoplasmosis to one of two one-year regimens of combination therapy (daily sulfadiazine, thrice weekly folinic acid, plus two versus six months of daily pyrimethamine followed by thrice weekly pyrimethamine for the remainder of the year). Compared with historical controls (untreated or treated for one month), combination treatment for 12 months was associated with improved neurologic, cognitive, and auditory outcomes at follow-up (average age 10.5 years) and prevention of new eye lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Major findings were as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Signs of active infection resolved within weeks in all treated infants who were evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/16\">",
"       16",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Among infants with no or mild disease at birth, all had normal cognitive, neurologic, and auditory outcomes; only 9 percent developed new eye lesions",
"     </li>",
"     <li>",
"      Among infants who had moderate or severe neurologic disease at birth, 72 percent had normal neurologic",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      cognitive outcomes; none had hearing loss; only 36 percent developed new eye lesions; but 85 percent had impaired vision (most infants with impaired vision had retinal disease at birth)",
"     </li>",
"     <li>",
"      There were 11 deaths (mortality of 9 percent); 9 of 11 deaths occurred in children with severe CNS disabilities",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient population of the NCCCTS was heterogeneous and symptomatic. In contrast, the 49 infants treated by the New England Regional Toxoplasma Working Group were identified only through serologic screening and had mild or subclinical infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/12\">",
"     12",
"    </a>",
"    ]. Although they did not have apparent disease at birth, further evaluation after being identified by serologic screening showed some combination of elevation of CSF protein, intracranial calcifications, or retinal lesions in 40 percent of the infants. Most of the infants were treated for one year (one infant died of a viral infection at two month of age; the parents of four discontinued treatment after six to eight months), but the regimens varied at the discretion of the infectious disease consultant; 40 of the 49 infants had the same regimen of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    daily for six months followed by pyrimethamine every other day for six months,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    twice daily for 12 months, and folinic acid thrice weekly to daily (adjusted for hematologic changes). After treatment, only one child had a neurologic deficit (hemiplegia that was attributed to a cerebral lesion present at birth). Among the 39 children who had ophthalmologic follow-up at one to six years of age, four had lesions that may have developed postnatally. These findings suggest that early treatment of asymptomatic infants may reduce long-term sequelae.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829795\">",
"    <span class=\"h3\">",
"     Adverse effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;The main side effect of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    is neutropenia, which often occurs in conjunction with a viral illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7,12,24\">",
"     7,12,24",
"    </a>",
"    ]. Neutropenia generally resolves when the folinic acid dose is increased. In some cases, modification of the pyrimethamine dose is required. Other adverse effects may include aplastic anemia, hepatotoxicity, and hypersensitivity.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     Sulfadiazine",
"    </a>",
"    -associated neutropenia should be considered if neutropenia persists despite increased doses of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?21/31/22005?source=see_link\">",
"     folic acid",
"    </a>",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    temporary discontinuation of pyrimethamine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Administration of a second sulfonamide drug (eg,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/23/41336?source=see_link\">",
"     trimethoprim-sulfamethoxazole",
"    </a>",
"    ) during combination therapy with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    -",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    should be avoided because it may result in sustained bone marrow suppression [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829802\">",
"    <span class=\"h3\">",
"     Therapeutic monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Complete blood counts (CBC) should be monitored during therapy to evaluate drug-induced neutropenia and hemolysis (for patients with G6D deficiency). We suggest that CBC be obtained:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once to twice per week after starting daily",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      ; the CBC can be spaced to every one to two weeks if the counts remain stable",
"     </li>",
"     <li>",
"      Once or twice per month when taking",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      every other day",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The more frequent intervals should be used if there is an intercurrent illness or neutropenia. The folinic acid (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=see_link\">",
"     leucovorin",
"    </a>",
"    ) dose should be increased if the ANC falls below 1000",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     Pyrimethamine",
"    </a>",
"    should be temporarily withheld if the ANC is below 500",
"    <span class=\"nowrap\">",
"     cells/microL.",
"    </span>",
"    Persistent neutropenia despite withholding of pyrimethamine may be caused by",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Periodic measurement of serum liver and renal function tests (aspartate transaminase and alanine transaminase or gamma-glutamyl transferase; bilirubin; alkaline phosphatase; blood urea nitrogen; and creatinine) may be useful, particularly if any abnormal results are detected on initial pretreatment screening. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link&amp;anchor=H1835019#H1835019\">",
"     \"Congenital toxoplasmosis: Clinical features and diagnosis\", section on 'Other laboratory tests'",
"    </a>",
"    .) Liver and renal function can be monitored every three to six months and as needed for follow-up of abnormal results.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829816\">",
"    <span class=\"h2\">",
"     Disease monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serologic follow-up is recommended for children with congenital toxoplasmosis until 18 months of age. Clinical follow-up is recommended throughout early childhood because of the risk of late sequelae. Routine ophthalmologic evaluations are especially important for infants and young children because they are unable to report changes in vision.",
"   </p>",
"   <p>",
"    We suggest the following schedule for follow-up:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum",
"      <em>",
"       Toxoplasma",
"      </em>",
"      -specific IgG and IgM determinations every three to six months until therapy has been completed. This is especially important for highly suspected, but unconfirmed, cases. Serology should be obtained at the conclusion of treatment and then repeated at one month, three months, and six months off therapy. Rebound rise in",
"      <em>",
"       Toxoplasma",
"      </em>",
"      -specific IgM levels is commonly seen following treatment. The clinical importance of IgM rebound is uncertain. Similarly, some children have",
"      <em>",
"       Toxoplasma",
"      </em>",
"      -specific IgG rebound several months after completion of therapy, the clinical significance of which is uncertain [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7,26,27\">",
"       7,26,27",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link&amp;anchor=H11764060#H11764060\">",
"       \"Congenital toxoplasmosis: Clinical features and diagnosis\", section on 'Serology'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Periodic physical examination, including neurodevelopmental assessments, with a particular emphasis on late ophthalmologic and neurologic manifestations, including evaluation of hearing. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link&amp;anchor=H21359969#H21359969\">",
"       \"Congenital toxoplasmosis: Clinical features and diagnosis\", section on 'Late manifestations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=see_link&amp;anchor=H18501566#H18501566\">",
"       \"Developmental-behavioral surveillance and screening in primary care\", section on 'When to perform developmental-behavioral screening'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Repeated eye examinations by an ophthalmologist experienced with identifying",
"      <em>",
"       Toxoplasma",
"      </em>",
"      chorioretinal lesions in infants and toddlers should be obtained every 3 months until 18 months of life, then every 6 to 12 months. The frequency of examinations should be adjusted as needed if retinal disease is present. Ophthalmologic examination should be performed earlier than scheduled if any symptoms that may be related to ocular disease occur. Some specialists recommend ophthalmology follow-up every three to six months until the child is old enough to report vision changes reliably [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Pediatric neurology examination every three to six months until one to two years of age. The frequency and duration of pediatric neurology follow-up are determined by the presence of neurologic abnormalities.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829823\">",
"    <span class=\"h2\">",
"     Treatment of new-onset chorioretinitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;New-onset active chorioretinitis occurring beyond the initial period of treatment should be treated with combination",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     pyrimethamine",
"    </a>",
"    (plus folinic acid) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    therapy. Most experts also treat vision-threatening lesions with",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     prednisone",
"    </a>",
"    until acute inflammation resolves. The doses are as follows [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"       Pyrimethamine",
"      </a>",
"      2",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 50",
"      <span class=\"nowrap\">",
"       mg/dose)",
"      </span>",
"      once daily for two days; then 1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      (maximum 25",
"      <span class=\"nowrap\">",
"       mg/dose)",
"      </span>",
"      once daily",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"       Sulfadiazine",
"      </a>",
"      75",
"      <span class=\"nowrap\">",
"       mg/kg,",
"      </span>",
"      then 12 hours later 50",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      twice per day",
"     </li>",
"     <li>",
"      Folinic acid (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=see_link\">",
"       leucovorin",
"      </a>",
"      ) 10 mg three times per week",
"     </li>",
"     <li>",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"       Prednisone",
"      </a>",
"      1",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day divided in two doses; maximum 40",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"     Pyrimethamine",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"     sulfadiazine",
"    </a>",
"    are continued until approximately two weeks after acute inflammation has resolved [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/6\">",
"     6",
"    </a>",
"    ]. Folinic acid is continued during pyrimethamine therapy and for one week after pyrimethamine is discontinued.",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?28/23/29047?source=see_link\">",
"     Prednisone",
"    </a>",
"    is continued until inflammation subsides and then is rapidly tapered.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6012039\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis in untreated infants with overt congenital toxoplasmosis disease at birth is poor. Untreated infants with subclinical infection may develop chorioretinitis, seizures, and severe psychomotor retardation. (See",
"    <a class=\"local\" href=\"#H4829752\">",
"     'Natural history of untreated disease'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Among treated infants, overall ocular prognosis usually is satisfactory, although late-onset retinal lesions and relapse can occur many years after birth [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Treatment may result in diminution or resolution of intracranial calcifications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/31\">",
"     31",
"    </a>",
"    ]. Infants with severe central nervous system disease apparent at birth tend to have more neurologic complications than those with subclinical infection, although some may do better than anticipated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7,13\">",
"     7,13",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    Treated infants remain at risk for developing sequelae later in life [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/6,25\">",
"     6,25",
"    </a>",
"    ]. Currently available antiparasitic drugs are active against the tachyzoite form of",
"    <em>",
"     T. gondii",
"    </em>",
"    but do not effectively eradicate the bradyzoite form from the CNS and eye. Thus, recurrence of ocular disease may occur after cessation of treatment. Chorioretinitis can result in retinal damage and loss of vision, which should be monitored closely. In a survey of 102 adults (18 to 31 years of age) who were treated for congenital toxoplasmosis (pre-",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    postnatally) in France, 11.8 percent had neurologic effects (intracranial calcifications or hydrocephalus), 60 percent had ocular lesions, but only 12.7 percent had reduced visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H4829816\">",
"     'Disease monitoring'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Risk factors for poor outcome include delay in the diagnosis and initiation of treatment, prolonged uncorrected hydrocephalus, cerebrospinal fluid protein &gt;1",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    cerebral atrophy, and extensive visual impairment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/7\">",
"     7",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6012724\">",
"     'Efficacy'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829830\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6015695\">",
"    <span class=\"h2\">",
"     Avoidance of exposure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Avoiding exposure to sources of",
"    <em>",
"     Toxoplasma",
"    </em>",
"    is an important way to prevent infection. This is particularly important for seronegative women of childbearing age and immunocompromised patients. Specific avoidance measures are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link&amp;anchor=H19#H19\">",
"     \"Toxoplasmosis and pregnancy\", section on 'Prevention'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H153221956\">",
"    <span class=\"h2\">",
"     Maternal screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of toxoplasmosis during pregnancy and screening pregnant women for toxoplasmosis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link&amp;anchor=H7#H7\">",
"     \"Toxoplasmosis and pregnancy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829837\">",
"    <span class=\"h2\">",
"     Prenatal treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of maternal toxoplasmosis during pregnancy to prevent fetal infection is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link&amp;anchor=H13#H13\">",
"     \"Toxoplasmosis and pregnancy\", section on 'Rationale for prenatal treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=see_link&amp;anchor=H14#H14\">",
"     \"Toxoplasmosis and pregnancy\", section on 'Treatment regimens'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829851\">",
"    <span class=\"h2\">",
"     Isolation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Standard precautions are recommended. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link&amp;anchor=H2#H2\">",
"     \"General principles of infection control\", section on 'Standard precautions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4829858\">",
"    <span class=\"h2\">",
"     Newborn screening",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some regions of the United States (eg, New England) and some European countries (eg, France, Austria) have implemented routine neonatal screening for toxoplasmosis to identify infants for early treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7672/abstract/12,33\">",
"     12,33",
"    </a>",
"    ]. Neonatal screening involves performance of a",
"    <em>",
"     Toxoplasma",
"    </em>",
"    IgM immunoassay on blood specimens routinely collected for metabolic screening. Positive screens are followed up with serologic testing of the infant and mother to confirm the diagnosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=see_link&amp;anchor=H11762879#H11762879\">",
"     \"Congenital toxoplasmosis: Clinical features and diagnosis\", section on 'Evaluation and diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4830879\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of children with untreated symptomatic congenital toxoplasmosis develop serious long-term sequelae, including intellectual disability, seizures, motor deficits, impaired vision, hydrocephalus, and hearing loss. These sequelae also occur in children with subclinical infection, but it is not possible to predict their likelihood. (See",
"      <a class=\"local\" href=\"#H4829752\">",
"       'Natural history of untreated disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment with antiparasitic therapy for infants in whom a diagnosis of congenital toxoplasmosis is confirmed or highly likely, as defined in the text (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4829774\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The preferred antiparasitic regimen includes",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      plus",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      (or sulfamerazine or sulfamethazine) and folinic acid (",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?3/56/3974?source=see_link\">",
"       leucovorin",
"      </a>",
"      ). The optimal doses and duration are not definitively established. We suggest that treatment be continued for one year. (See",
"      <a class=\"local\" href=\"#H4829781\">",
"       'Treatment regimen'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Combination treatment with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?7/50/7973?source=see_link\">",
"       pyrimethamine",
"      </a>",
"      and",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=see_link\">",
"       sulfadiazine",
"      </a>",
"      for one year has been associated with improved long-term neurologic, cognitive, and auditory outcomes and prevention of new eye lesions compared with untreated historical controls. (See",
"      <a class=\"local\" href=\"#H6012724\">",
"       'Efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Complete blood counts should be monitored during therapy to evaluate drug-induced neutropenia, and hemolysis (for patients with G6PD deficiency). (See",
"      <a class=\"local\" href=\"#H4829802\">",
"       'Therapeutic monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Clinical monitoring for late ophthalmologic and neurodevelopmental manifestations of congenital toxoplasmosis is recommended throughout early childhood. (See",
"      <a class=\"local\" href=\"#H4829816\">",
"       'Disease monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Treated infants remain at risk for long-term sequelae, especially new-onset ocular disease; recurrence of ocular disease may occur after cessation of treatment. Long-term neurologic deficits usually correlate with the severity of brain injury before the initiation of treatment. Risk factors for poor outcome include delay in the diagnosis and initiation of treatment, prolonged uncorrected hydrocephalus, cerebrospinal fluid protein",
"      <span class=\"nowrap\">",
"       &gt;1g/dL,",
"      </span>",
"      cerebral atrophy, and extensive visual impairment. (See",
"      <a class=\"local\" href=\"#H6012039\">",
"       'Prognosis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Eichenwald HF. A study of congenital toxoplasmosis with particular emphasis on clinical manifestations, sequelae and therapy. In: Human Toxoplasmosis, Siim JC (Ed), Munksgaard, Copenhagen 1959.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/2\">",
"      Wilson CB, Remington JS, Stagno S, Reynolds DW. Development of adverse sequelae in children born with subclinical congenital Toxoplasma infection. Pediatrics 1980; 66:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/3\">",
"      Koppe JG, Loewer-Sieger DH, de Roever-Bonnet H. Results of 20-year follow-up of congenital toxoplasmosis. Lancet 1986; 1:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/4\">",
"      Labadie MD, Hazemann JJ. [Contribution of health check-ups in children to the detection and epidemiologic study of congenital toxoplasmosis]. Ann Pediatr (Paris) 1984; 31:823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/5\">",
"      Stagno S, Reynolds DW, Amos CS, et al. Auditory and visual defects resulting from symptomatic and subclinical congenital cytomegaloviral and toxoplasma infections. Pediatrics 1977; 59:669.",
"     </a>",
"    </li>",
"    <li>",
"     Remington JS, McLeod R, Wilson CB, Desmonts G. Toxoplasmosis. In: Infectious Diseases of the Fetus and Newborn Infant, 7th ed, Remington, JS, Klein, JO, Wilson, CB, et al (Eds), Elsevier Saunders, Philadelphia 2011. p.918.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/7\">",
"      McAuley J, Boyer KM, Patel D, et al. Early and longitudinal evaluations of treated infants and children and untreated historical patients with congenital toxoplasmosis: the Chicago Collaborative Treatment Trial. Clin Infect Dis 1994; 18:38.",
"     </a>",
"    </li>",
"    <li>",
"     American Academy of Pediatrics. Toxoplasma gondii infections (toxoplasmosis). In: Red Book: 2012 Report of the Committee on Infectious Diseases, 29th, Pickering LK.  (Ed), American Academy of Pediatrics, Elk Grove Village, IL 2012. p.720.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/9\">",
"      Mofenson LM, Brady MT, Danner SP, et al. Guidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. MMWR Recomm Rep 2009; 58:1.",
"     </a>",
"    </li>",
"    <li>",
"     McAuley JB, Boyer KM, Remington JS, McLeod RL. Toxoplasmosis. In: Textbook of Pediatric Infectious Diseases, 6th ed, Feigin RD, Cherry JD, Demmler-Harrison GJ, Kaplan SL (Eds), Saunders, Philadelphia 2009. p.2954.",
"    </li>",
"    <li>",
"     Contopoulos-Ioannidis D, Montoya JG. Toxoplasma gondii (toxoplasmosis). In: Principles and Practice of Pediatric Infectious Diseases, 4th, Long SS, Pickering LK, Prober CG.  (Eds), Elsevier Saunders, Edinburgh 2012. p.1308.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/12\">",
"      Guerina NG, Hsu HW, Meissner HC, et al. Neonatal serologic screening and early treatment for congenital Toxoplasma gondii infection. The New England Regional Toxoplasma Working Group. N Engl J Med 1994; 330:1858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/13\">",
"      McLeod R, Boyer K, Karrison T, et al. Outcome of treatment for congenital toxoplasmosis, 1981-2004: the National Collaborative Chicago-Based, Congenital Toxoplasmosis Study. Clin Infect Dis 2006; 42:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/14\">",
"      Roizen N, Swisher CN, Stein MA, et al. Neurologic and developmental outcome in treated congenital toxoplasmosis. Pediatrics 1995; 95:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/15\">",
"      Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS. A randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. The California Collaborative Treatment Group. Ann Intern Med 1992; 116:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/16\">",
"      McLeod R, Mack D, Foss R, et al. Levels of pyrimethamine in sera and cerebrospinal and ventricular fluids from infants treated for congenital toxoplasmosis. Toxoplasmosis Study Group. Antimicrob Agents Chemother 1992; 36:1040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/17\">",
"      Katlama C, De Wit S, O'Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clin Infect Dis 1996; 22:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/18\">",
"      Dannemann BR, Israelski DM, Remington JS. Treatment of toxoplasmic encephalitis with intravenous clindamycin. Arch Intern Med 1988; 148:2477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/19\">",
"      Gilbert R, Dezateux C. Newborn screening for congenital toxoplasmosis: feasible, but benefits are not established. Arch Dis Child 2006; 91:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/20\">",
"      Kravetz J. Congenital toxoplasmosis. Clin Evid (Online) 2008; 2008.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/21\">",
"      Mack DG, McLeod R. New micromethod to study the effect of antimicrobial agents on Toxoplasma gondii: comparison of sulfadoxine and sulfadiazine individually and in combination with pyrimethamine and study of clindamycin, metronidazole, and cyclosporin A. Antimicrob Agents Chemother 1984; 26:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/22\">",
"      Weiss LM, Harris C, Berger M, et al. Pyrimethamine concentrations in serum and cerebrospinal fluid during treatment of acute Toxoplasma encephalitis in patients with AIDS. J Infect Dis 1988; 157:580.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/23\">",
"      Luft BJ, Remington JS. Toxoplasmic encephalitis in AIDS. Clin Infect Dis 1992; 15:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/24\">",
"      Kieffer F, Thulliez P, Br&eacute;zin A, et al. [Treatment of subclinical congenital toxoplasmosis by sulfadiazine and pyrimethamine continuously during 1 year: apropos of 46 cases]. Arch Pediatr 2002; 9:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/25\">",
"      Guerina NG. Congenital infection with Toxoplasma gondii. Pediatr Ann 1994; 23:138.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/26\">",
"      Wallon M, Cozon G, Ecochard R, et al. Serological rebound in congenital toxoplasmosis: long-term follow-up of 133 children. Eur J Pediatr 2001; 160:534.",
"     </a>",
"    </li>",
"    <li>",
"     Lynfield R, Ogunmodede F, Guerina NG. Toxoplasmosis. In: Oski's Pediatrics Principles and Practice, 4th ed, McMillan JA, Feigin RD, DeAngelis CD, Jones MD (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2006. p.1351.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/28\">",
"      Mets MB, Holfels E, Boyer KM, et al. Eye manifestations of congenital toxoplasmosis. Am J Ophthalmol 1996; 122:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/29\">",
"      Wallon M, Kodjikian L, Binquet C, et al. Long-term ocular prognosis in 327 children with congenital toxoplasmosis. Pediatrics 2004; 113:1567.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/30\">",
"      Berr&eacute;bi A, Assouline C, Bessi&egrave;res MH, et al. Long-term outcome of children with congenital toxoplasmosis. Am J Obstet Gynecol 2010; 203:552.e1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/31\">",
"      Patel DV, Holfels EM, Vogel NP, et al. Resolution of intracranial calcifications in infants with treated congenital toxoplasmosis. Radiology 1996; 199:433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/32\">",
"      Peyron F, Garweg JG, Wallon M, et al. Long-term impact of treated congenital toxoplasmosis on quality of life and visual performance. Pediatr Infect Dis J 2011; 30:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7672/abstract/33\">",
"      Bessi&egrave;res MH, Berrebi A, Rolland M, et al. Neonatal screening for congenital toxoplasmosis in a cohort of 165 women infected during pregnancy and influence of in utero treatment on the results of neonatal tests. Eur J Obstet Gynecol Reprod Biol 2001; 94:37.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15835 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-77.94.48.4-442DE206A6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7672=[""].join("\n");
var outline_f7_31_7672=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H4830879\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4829118\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4829752\">",
"      NATURAL HISTORY OF UNTREATED DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4829759\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4829767\">",
"      Antiparasitic therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4829774\">",
"      - Indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4829781\">",
"      - Treatment regimen",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H6013042\">",
"      Special considerations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6012724\">",
"      - Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4829795\">",
"      - Adverse effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4829802\">",
"      - Therapeutic monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4829816\">",
"      Disease monitoring",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4829823\">",
"      Treatment of new-onset chorioretinitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6012039\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4829830\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6015695\">",
"      Avoidance of exposure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H153221956\">",
"      Maternal screening",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4829837\">",
"      Prenatal treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4829851\">",
"      Isolation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4829858\">",
"      Newborn screening",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4830879\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/12/43208?source=related_link\">",
"      Congenital toxoplasmosis: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/49/26394?source=related_link\">",
"      Developmental-behavioral surveillance and screening in primary care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?38/7/39029?source=related_link\">",
"      Sulfadiazine: Pediatric drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/39/22137?source=related_link\">",
"      Toxoplasmosis and pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/22/33129?source=related_link\">",
"      Toxoplasmosis in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/38/16999?source=related_link\">",
"      Toxoplasmosis in immunocompetent hosts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_31_7673="Immunomodulator therapy in Crohn's disease";
var content_f7_31_7673=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Immunomodulator therapy in Crohn's disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7673/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7673/contributors\">",
"     Richard P MacDermott, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7673/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7673/contributors\">",
"     Paul Rutgeerts, MD, PhD, FRCP",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7673/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7673/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/31/7673/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 28, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Crohn's disease who remain refractory to therapy with steroids, 5-ASA agents, and antibiotics, or who depend upon steroids to control the disease are a common and challenging problem. Additional medical therapy is appropriate because surgery is accompanied by a high recurrence rate and many patients have already had previous resections.",
"   </p>",
"   <p>",
"    Several drugs have shown efficacy in this setting. The best studied and most commonly used are the immunomodulators (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , its metabolite 6-mercaptopurine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ), and the biologics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and certolizumab). These medications induce response and remission in a significant number of Crohn's disease patients. Furthermore, all are capable of inducing mucosal healing and modifying the disease course in a subset of Crohn's disease patients.",
"   </p>",
"   <p>",
"    The efficacy and toxicities of the commonly used immunomodulators (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    , 6-mercaptopurine, and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    ) as well as the less frequently used immunomodulator",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (FK506) and recommendations for their use will be reviewed here.",
"   </p>",
"   <p>",
"    Conventional and alternative treatments for Crohn's disease are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=see_link\">",
"     \"Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=see_link\">",
"     \"Investigational therapies in the medical management of Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of the anti-tumor necrosis factor (anti-TNF) agents,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (Remicade&reg;) and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    (Humira&reg;), are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=see_link\">",
"     \"Adalimumab for treatment of Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     AZATHIOPRINE AND 6-MERCAPTOPURINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     Azathioprine",
"    </a>",
"    (AZA) is a derivative of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/54/35685?source=see_link\">",
"     thioguanine",
"    </a>",
"    , a purine mimic antimetabolite [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/1\">",
"     1",
"    </a>",
"    ]. AZA is well absorbed from the gastrointestinal tract. It has a serum half-life of 0.2 to 0.5 hours, resulting in a biologic half-life of approximately 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/2\">",
"     2",
"    </a>",
"    ]. AZA is a prodrug; the action of glutathione in red blood cells causes the formation of the principal metabolite, 6-mercaptopurine (6-MP) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/1\">",
"     1",
"    </a>",
"    ]. Intracellular metabolites are responsible for the antineoplastic and immune modulating effects of AZA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/3\">",
"     3",
"    </a>",
"    ]. A review of the mechanism of action of azathioprine is also available elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=see_link\">",
"     \"Pharmacology and side effects of azathioprine when used in rheumatic diseases\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=see_link&amp;anchor=H2#H2\">",
"     \"Azathioprine and 6-mercaptopurine in inflammatory bowel disease\", section on 'Pharmacodynamics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    AZA and 6-MP have been used successfully in patients with Crohn's disease for:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Induction of remission in steroid refractory disease",
"     </li>",
"     <li>",
"      Maintenance of remission",
"     </li>",
"     <li>",
"      As a steroid sparing agent in patients who are steroid-dependent",
"     </li>",
"     <li>",
"      Fistulizing disease",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179162757\">",
"    <span class=\"h2\">",
"     Efficacy of AZA and 6-MP",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179164795\">",
"    <span class=\"h3\">",
"     Induction of remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment with AZA or 6-MP is more effective than placebo, but not all patients with Crohn's disease respond and the placebo response rate is substantial. The efficacy of AZA and 6-MP has been shown in multiple uncontrolled clinical trials, and at least nine controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/4-11\">",
"     4-11",
"    </a>",
"    ], although results differed significantly among them. Two trials used 6-MP [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/7,11\">",
"     7,11",
"    </a>",
"    ]; the others used",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ; however, these two drugs are probably equally effective when given in equivalent doses.",
"   </p>",
"   <p>",
"    The main reason for the differences among these studies probably reflects variability in disease severity, location, and natural history. Differences in study design, use of concomitant drug therapy, and clinical endpoints in the individual studies also limit direct comparison among the studies. As an example, among the eight controlled trials, only four used improvement in validated indices of Crohn's disease activity as an outcome measure. The duration of the studies also varied significantly ranging from 2 to 12 months, as did the dose of AZA and 6-MP (2.0 to 3.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for AZA and 50",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    to 1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day for 6-MP).",
"   </p>",
"   <p>",
"    In a meta-analysis of eight randomized placebo-controlled trials, both AZA and 6-MP were effective therapy for inducing remission in active Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/12\">",
"     12",
"    </a>",
"    ]. The odds ratio of a response to therapy compared to placebo was 2.4. This corresponded to a number needed to treat of about five to observe an effect of therapy in one patient. A steroid sparing effect was seen with an odds ratio of 3.7. The number needed to treat to observe steroid sparing in one patient was 3. Treatment was also associated with a significantly higher rate of fistula healing. The peak response to treatment occurred after &gt;17 weeks of therapy. A randomized controlled trial found that intravenous loading of AZA did not decrease the time to response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/13\">",
"     13",
"    </a>",
"    ]. A second meta-analysis with five studies (four of which were included in the meta-analysis above) found that the odds of",
"    <strong>",
"     not",
"    </strong>",
"    being in remission were lower among patients treated with AZA or 6-MP compared with placebo (OR 0.42, 95% CI 0.2-0.89), though there was no difference in relative risk (RR 0.87, 95% CI 0.71-1.06) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=see_link&amp;anchor=H9#H9\">",
"     \"Glossary of common biostatistical and epidemiological terms\", section on 'Terms used to describe the magnitude of an effect'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite the evidence of benefit, several questions remain unanswered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The minimum effective dose (or whether leukopenia is needed) for inducing remission is unknown. The observation that higher doses are more effective for maintaining remission suggests that a dose-response relationship probably also exists for the induction of remission (see",
"      <a class=\"local\" href=\"#H4\">",
"       'Maintenance of remission'",
"      </a>",
"      below). In one study, AZA was increased in 40 patients with active disease from 2.02",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily to 2.72",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily in one to four increments of 0.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily, and patients were followed over six months [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/15\">",
"       15",
"      </a>",
"      ]. Response to dose increase was noted in 28 percent while 43 percent had no benefit. Response was more likely for maximum doses less than or equal to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily than for higher doses, which were also associated with higher rates of adverse reactions.",
"     </li>",
"     <li>",
"      The influence of concomitant use of 5-ASA drugs, in combination with AZA or 6-MP on induction or maintenance of remission, remains unclear.",
"     </li>",
"     <li>",
"      The effectiveness of AZA or 6-MP on defined clinical manifestations of Crohn's disease (such as specific disease location, duration of disease, or extraintestinal manifestations) requires further study.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Maintenance of remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Controlled trials have evaluated the efficacy of AZA or 6-MP for the maintenance of remission in Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/4,9-11,16-18\">",
"     4,9-11,16-18",
"    </a>",
"    ]. The studies differed in their inclusion criteria (with or without steroids, prior",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    therapy) and outcome measures. Overall, AZA and 6-MP seem most efficacious for maintenance of remission after induction of remission with steroids [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/4,11\">",
"     4,11",
"    </a>",
"    ]. The benefit of AZA or 6-MP for the maintenance of remission has been demonstrated in meta-analyses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/14,19\">",
"     14,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One meta-analysis made the following observations [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/19\">",
"     19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      and 6-MP are effective for reducing the risk of Crohn's disease recurrence. The rate of remission maintenance was higher in patients receiving active treatment compared to patients who discontinued maintenance therapy with azathioprine or 6-MP. In terms of absolute benefit, approximately four to six patients would need long-term maintenance therapy to maintain remission in one patient. The maintenance of remission was dose-dependent for azathioprine. Patients receiving 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      of AZA per day were significantly more likely to maintain remission than those treated with lower doses (estimated odds ratio versus placebo of 4.13 for a dose of 2.5",
"      <span class=\"nowrap\">",
"       mg/kg/day",
"      </span>",
"      versus 1.20 for a dose of 1.0",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      per day).",
"     </li>",
"     <li>",
"      Steroids were more likely to be reduced and discontinued in patients receiving AZA (87 versus 53 percent with placebo).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Prevention of recurrence following surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following surgical resection, AZA or 6-MP may be effective for maintaining remission in the involved areas of bowel that were not resected. AZA and 6-MP have also been tested in patients who underwent a curative resection. In a meta-analysis of four controlled trials, AZA was more effective than placebo, with or without antibiotic induction therapy or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    , for the prevention of both clinical and endoscopic postoperative recurrence in Crohn's disease at one and two years [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/20\">",
"     20",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/50/809?source=see_link\">",
"     \"Medical prophylaxis of postoperative Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Steroid sparing agent",
"    </span>",
"    &nbsp;&mdash;&nbsp;In two different meta-analyses, steroids were more likely to be reduced in patients receiving AZA for both induction of remission (65 versus 36 percent with placebo) and maintenance of remission (87 versus 53 percent with placebo) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/12,19\">",
"     12,19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Furthermore, a randomized controlled trial in 55 children with newly diagnosed moderate to severe Crohn's disease suggested that early use of 6-MP could significantly reduce exposure to glucocorticoids during the first year after diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/11\">",
"     11",
"    </a>",
"    ]. Children receiving 6-MP required a significantly shorter period and cumulative dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    at 6, 12, and 18 months.",
"   </p>",
"   <p>",
"    In addition to reducing long-term side effects associated with steroid therapy, an early switch to AZA may be more efficacious for managing pediatric Crohn's disease. In a population-based cohort study of 404 children with Crohn's disease, those taking AZA were less likely to have surgery compared to those treated with glucocorticoid therapy (0.5 versus 3 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Fistula treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although antibiotics remain the first line of treatment, AZA and 6-MP have shown to be effective treatments for patients with fistulas in Crohn's disease. 6-MP (1.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) for three to six months has been used successfully to treat perianal fistulas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Treatment with 6-MP was more effective in closing fistulas (31 versus 6 percent with placebo) in a two-year double-blind crossover study of 83 chronically ill patients with Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/7\">",
"     7",
"    </a>",
"    ]. A meta-analysis of five randomized controlled trials revealed AZA or 6-MP treatment resulted in complete healing or decreased discharge (54 versus 21 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/24\">",
"     24",
"    </a>",
"    ]. In another study of 94 patients with perianal Crohn's disease, 29 percent demonstrated improvement with AZA or 6-MP therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <span class=\"nowrap\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11188328#H11188328\">",
"      \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Fistulae'",
"     </a>",
"     .)",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22270073\">",
"    <span class=\"h2\">",
"     Efficacy of AZA and 6-MP in combination with anti-TNF therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;AZA/6-MP",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    show synergistic effects. In the SONIC study in patients with early Crohn&rsquo;s disease na&iuml;ve to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    and infliximab, the combination was superior to infliximab alone or azathioprine alone for inducing and maintaining steroid free remission and mucosal healing [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link&amp;anchor=H12#H12\">",
"     \"Infliximab in Crohn's disease\", section on 'Use of immunosuppressive agents in combination with infliximab'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The combined use of",
"    <span class=\"nowrap\">",
"     AZA/6-MP",
"    </span>",
"    with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    also decreases the rate of antibody formation against infliximab and is associated with higher levels of the drug and superior efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/27\">",
"     27",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     METHOTREXATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     Methotrexate",
"    </a>",
"    (MTX) is a structural analogue of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     folic acid",
"    </a>",
"    that can competitively inhibit the binding of dihydrofolic acid (FH2) to the enzyme dihydrofolate reductase (DHFR). DHFR is responsible for reducing FH2 to folinic acid (FH4), the active intracellular metabolite. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=see_link\">",
"     \"Use of methotrexate in the treatment of rheumatoid arthritis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Despite an understanding of the cellular action of MTX, the mechanism by which it improves inflammatory bowel disease is not certain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/28\">",
"     28",
"    </a>",
"    ]. One possibility is enhanced extracellular concentrations of adenosine, an autacoid with robust antiinflammatory activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Other mechanisms may include the inhibition of methylation reactions vital for cellular activities and replication, and the clonal deletion via apoptosis of activated peripheral T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/31\">",
"     31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179164881\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Induction of remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;MTX has been used in several inflammatory diseases, including rheumatoid arthritis, psoriasis, and primary biliary cirrhosis. (See appropriate topic reviews). The American Gastroenterological Association has issued guidelines for its use in IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/32\">",
"     32",
"    </a>",
"    ]. At least three controlled trials of MTX have shown variable efficacy for the treatment of active Crohn's disease in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/33-35\">",
"     33-35",
"    </a>",
"    ]. A systematic review [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/36\">",
"     36",
"    </a>",
"    ] concluded that a single controlled trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/33\">",
"     33",
"    </a>",
"    ] supported the efficacy of intramuscular",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    with remission rates of 40 percent versus 19 percent in the placebo group. The number needed to treat for one Crohn's disease patient to attain induction of remission is 5 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/36\">",
"     36",
"    </a>",
"    ]. There is no evidence for use of lower-dose oral methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/36\">",
"     36",
"    </a>",
"    ]. A meta-analysis found that the odds for not being in remission were lower for MTX than placebo (OR 0.47), but the results were largely driven by one positive trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/14,33\">",
"     14,33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    25 mg IM weekly is used for induction. Some clinicians have also reported excellent results using subcutaneous administration of methotrexate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Maintenance of remission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (MTX) for maintenance of remission in patients with Crohn's disease has been observed in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/38-41\">",
"     38-41",
"    </a>",
"    ] and evaluated in randomized trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/34,42\">",
"     34,42",
"    </a>",
"    ]. The best data come from a double-blind, multicenter randomized trial of 76 patients with Crohn's disease who were in remission, as defined by a Crohn's Disease Activity Index score &le;150 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/42\">",
"     42",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link&amp;anchor=H11240437#H11240437\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\", section on 'Definitions of severity'",
"    </a>",
"    .) The patients were randomly assigned to MTX (15 mg IM once weekly) or placebo. At 40 weeks, the patients treated with MTX were significantly more likely to be in remission (65 versus 39 percent). There were no serious adverse effects in patients treated with MTX.",
"   </p>",
"   <p>",
"    Another randomized trial found that while oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    was associated with a lower rate of relapse compared to placebo (10 versus 33 percent), the difference was not statistically significant because the number of relapses was small, and approximately one-third of patients did not complete the study [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A systematic review concluded that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    (15 mg IM weekly) was significantly more effective than placebo in maintaining remission in Crohn's disease with an odds ratio of 3.11 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/43\">",
"     43",
"    </a>",
"    ]. The number needed to treat in order to prevent one relapse was 4.",
"   </p>",
"   <p>",
"    As a result of these findings, the maintenance dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    used for maintenance of remission is between 15 and 25 mg IM once weekly. In a case series of 63 patients with active Crohn's disease treated with methotrexate for up to three years, the cumulative probability of maintaining remission was 95, 90, 71, and 63 percent at six months, one, two, and three years of treatment, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/44\">",
"     44",
"    </a>",
"    ]. However, its use was limited due to side effects in 79 percent of patients, leading to withdrawal in 33 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several side effects have been described in patients taking MTX, although therapy is usually well tolerated. Adverse reactions include nausea, abnormalities in liver enzymes, opportunistic infections, bone marrow depression, and interstitial pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=see_link\">",
"     \"Major side effects of low-dose methotrexate\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The most frequent side effects occurring in one controlled trial of patients with Crohn's disease were nausea, vomiting, abdominal distress, a rise in serum aminotransferases, headache, and rash, which required discontinuation of treatment in 17 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/33\">",
"     33",
"    </a>",
"    ].",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/61/9174?source=see_link\">",
"     Folic acid",
"    </a>",
"    at a dose of 1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    should be given routinely to all patients taking MTX since it may reduce nausea, vomiting, and abdominal distress.",
"   </p>",
"   <p>",
"    Long-term use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    has been associated with hepatotoxicity. The risk of hepatotoxicity may depend upon the specific disease being treated, the dose, and the duration of therapy, as well as comorbid conditions such as obesity, diabetes, and alcoholism. The risk of hepatotoxicity due to methotrexate in patients with inflammatory bowel disease is unknown, and is considered to be too low to justify surveillance liver biopsies based upon the cumulative dose [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/45\">",
"     45",
"    </a>",
"    ]. Methotrexate is teratogenic and should be avoided in men and women who want to conceive. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=see_link\">",
"     \"Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     CYCLOSPORINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in organ transplant recipients led to evaluation of its use in inflammatory bowel disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/32\">",
"     32",
"    </a>",
"    ]. The role of cyclosporine in the management of patients with Crohn&rsquo;s disease has not been established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179164896\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;A meta-analysis of the four controlled trials [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/46-49\">",
"     46-49",
"    </a>",
"    ] concluded that low dose (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    was not effective for the induction of remission in Crohn's disease and that oral dosing at higher levels or parenteral administration have not been evaluated adequately [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, when considering alternative medical options available to treat patients with active or refractory disease, oral",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    has little if any role.",
"   </p>",
"   <p>",
"    There are no randomized trials of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    in patients with severe Crohn&rsquo;s colitis. One retrospective study of 48 patients with severe Crohn&rsquo;s colitis or indeterminate colitis favoring Crohn&rsquo;s demonstrated that intravenous cyclosporine resulted in avoidance of in-hospital colectomy in 88 percent of patients but the colectomy rate at 12 months was 41 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/51\">",
"     51",
"    </a>",
"    ]. Other small observational studies have demonstrated low response rates to intravenous cyclosporine and high relapse rates after discontinuation of cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/52,53\">",
"     52,53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    for fistulizing Crohn's disease is suggested only in uncontrolled case series [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/52,54,55\">",
"     52,54,55",
"    </a>",
"    ], and other therapies have demonstrated higher efficacy in these patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/32\">",
"     32",
"    </a>",
"    ]. In addition, high relapse rates have been noted on discontinuation of cyclosporine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/52\">",
"     52",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11188328#H11188328\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Fistulae'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179164889\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     Cyclosporine",
"    </a>",
"    is associated with multiple side effects and drug interactions. These include opportunistic infections, nephrotoxicity, hypertension, seizures, peripheral neuropathy, and anaphylaxis. Blood levels of cyclosporine must be monitored carefully during its administration. A serum cholesterol should be checked before giving the drug; low cholesterol levels can predispose to seizures.",
"   </p>",
"   <p>",
"    As a result of its side effect profile and the availability of alternative therapies for fistulizing Crohn's disease,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    is rarely used for Crohn's disease and its role should be limited to selected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TACROLIMUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     Tacrolimus",
"    </a>",
"    (FK506) is an immunomodulator with similar mechanisms of action as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    but better oral absorption [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/58-60\">",
"     58-60",
"    </a>",
"    ]. Tacrolimus has been reported to be useful for the treatment of refractory IBD in multiple studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/32,60-65\">",
"     32,60-65",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179164910\">",
"    <span class=\"h2\">",
"     Efficacy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The only controlled trial in Crohn's disease included 48 patients with draining perianal or enterocutaneous fistulas who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    (0.2 mg per kg per day) or placebo for 10 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/66\">",
"     66",
"    </a>",
"    ]. Fistula improvement occurred significantly more often in the tacrolimus group (43 versus 8 percent) but rates of remission were not significantly different.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H179164917\">",
"    <span class=\"h2\">",
"     Toxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adverse effects associated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    included headache, increased serum creatinine, insomnia, leg cramps, paresthesias and tremors. These were generally managed with dose reduction. Multicenter trials are ongoing and should further clarify the role of this drug for Crohn's disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=see_link\">",
"     \"Pharmacology and side effects of cyclosporine and tacrolimus\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SIROLIMUS AND EVEROLIMUS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    in Crohn's disease is limited to case reports. In one such report, it was associated with clinical improvement in a woman with severe, colonic, and perianal disease who had lost response to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The safety and tolerability of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    (6",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"     azathioprine",
"    </a>",
"    (2.5",
"    <span class=\"nowrap\">",
"     mg/kg)",
"    </span>",
"    were comparable in a placebo-controlled comparison study that was terminated early due to lack of efficacy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7673/abstract/68\">",
"     68",
"    </a>",
"    ]. Everolimus was not more effective in achieving a steroid-free remission in active Crohn's disease than azathioprine but neither of the immunomodulators was significantly superior to placebo.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     ANTI-TNF THERAPIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     Infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/24/39303?source=see_link\">",
"     adalimumab",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/6/39014?source=see_link\">",
"     certolizumab pegol",
"    </a>",
"    are approved for treatment of Crohn's disease in adults in the United States. The use of these drugs in the management of Crohn's disease is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=see_link\">",
"     \"Adalimumab for treatment of Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link&amp;anchor=H11188279#H11188279\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\", section on 'Anti-TNF therapies'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       Azathioprine",
"      </a>",
"      (AZA) or 6-mercaptopurine (6-MP), compared with placebo, are associated with a higher overall response rate, a higher rate of fistula healing, and more frequent reduction in steroid use in patients with severe Crohn's disease. However, onset of action is slow (&gt;3 months). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Azathioprine and 6-mercaptopurine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      AZA and 6-MP are more effective than placebo in maintaining remission in patients who achieved remission with these drugs and in reducing steroid consumption in patients with severe Crohn's disease. The optimal duration of therapy is unknown. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Maintenance of remission'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      25 mg once a week given intramuscularly is more effective than placebo in inducing remission in patients with severe Crohn's disease. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      15 to 25 mg once a week given intramuscularly is effective in maintaining remission in patients with severe Crohn's disease who achieved remission with methotrexate. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Methotrexate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"       Tacrolimus",
"      </a>",
"      is effective in patients who are refractory to AZA, 6-MP,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       methotrexate",
"      </a>",
"      ,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      biologics. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Tacrolimus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"       Cyclosporine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       sirolimus",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      do not have an established role in the management of Crohn's disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Cyclosporine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19\">",
"       'Sirolimus and everolimus'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/1\">",
"      Elion GB. The purine path to chemotherapy. Science 1989; 244:41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/2\">",
"      Huskisson EC. Azathioprine. Clin Rheum Dis 1984; 10:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/3\">",
"      Nyhan WL, Sweetman L, Carpenter DG, et al. Effects of azathiprine in a disorder of uric acid metabolism and cerebral function. J Pediatr 1968; 72:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/4\">",
"      Candy S, Wright J, Gerber M, et al. A controlled double blind study of azathioprine in the management of Crohn's disease. Gut 1995; 37:674.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/5\">",
"      Ewe K, Press AG, Singe CC, et al. Azathioprine combined with prednisolone or monotherapy with prednisolone in active Crohn's disease. Gastroenterology 1993; 105:367.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/6\">",
"      Klein M, Binder HJ, Mitchell M, et al. Treatment of Crohn's disease with azathioprine: a controlled evaluation. Gastroenterology 1974; 66:916.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/7\">",
"      Present DH, Korelitz BI, Wisch N, et al. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med 1980; 302:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/8\">",
"      Rhodes J, Bainton D, Beck P, Campbell H. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2:1273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/9\">",
"      Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/10\">",
"      Willoughby JM, Beckett J, Kumar PJ, Dawson AM. Controlled trial of azathioprine in Crohn's disease. Lancet 1971; 2:944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/11\">",
"      Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn's disease. Gastroenterology 2000; 119:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/12\">",
"      Prefontaine E, Macdonald JK, Sutherland LR. Azathioprine or 6-mercaptopurine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2009; :CD000545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/13\">",
"      Sandborn WJ, Tremaine WJ, Wolf DC, et al. Lack of effect of intravenous administration on time to respond to azathioprine for steroid-treated Crohn's disease. North American Azathioprine Study Group. Gastroenterology 1999; 117:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/14\">",
"      Khan KJ, Dubinsky MC, Ford AC, et al. Efficacy of immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol 2011; 106:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/15\">",
"      Rayner CK, Hart AL, Hayward CM, et al. Azathioprine dose escalation in inflammatory bowel disease. Aliment Pharmacol Ther 2004; 20:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/16\">",
"      O'Donoghue DP, Dawson AM, Powell-Tuck J, et al. Double-blind withdrawal trial of azathioprine as maintenance treatment for Crohn's disease. Lancet 1978; 2:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/17\">",
"      Rosenberg JL, Levin B, Wall AJ, Kirsner JB. A controlled trial of azathioprine in Crohn's disease. Am J Dig Dis 1975; 20:721.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/18\">",
"      Vilien M, Dahlerup JF, Munck LK, et al. Randomized controlled azathioprine withdrawal after more than two years treatment in Crohn's disease: increased relapse rate the following year. Aliment Pharmacol Ther 2004; 19:1147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/19\">",
"      Prefontaine E, Sutherland LR, Macdonald JK, Cepoiu M. Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; :CD000067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/20\">",
"      Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/21\">",
"      Vernier-Massouille G, Balde M, Salleron J, et al. Natural history of pediatric Crohn's disease: a population-based cohort study. Gastroenterology 2008; 135:1106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/22\">",
"      Korelitz BI, Present DH. Favorable effect of 6-mercaptopurine on fistulae of Crohn's disease. Dig Dis Sci 1985; 30:58.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/23\">",
"      Jeshion WC, Larsen KL, Jawad AF, et al. Azathioprine and 6-mercaptopurine for the treatment of perianal Crohn's disease in children. J Clin Gastroenterol 2000; 30:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/24\">",
"      Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med 1995; 123:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/25\">",
"      Lecomte T, Contou JF, Beaugerie L, et al. Predictive factors of response of perianal Crohn's disease to azathioprine or 6-mercaptopurine. Dis Colon Rectum 2003; 46:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/26\">",
"      Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med 2010; 362:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/27\">",
"      Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/28\">",
"      Egan LJ, Sandborn WJ. Methotrexate for inflammatory bowel disease: pharmacology and preliminary results. Mayo Clin Proc 1996; 71:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/29\">",
"      Morabito L, Montesinos MC, Schreibman DM, et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5'-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998; 101:295.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/30\">",
"      Cronstein BN. Molecular therapeutics. Methotrexate and its mechanism of action. Arthritis Rheum 1996; 39:1951.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/31\">",
"      Genestier L, Paillot R, Fournel S, et al. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest 1998; 102:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/32\">",
"      Lichtenstein GR, Abreu MT, Cohen R, et al. American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006; 130:940.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/33\">",
"      Feagan BG, Rochon J, Fedorak RN, et al. Methotrexate for the treatment of Crohn's disease. The North American Crohn's Study Group Investigators. N Engl J Med 1995; 332:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/34\">",
"      Oren R, Moshkowitz M, Odes S, et al. Methotrexate in chronic active Crohn's disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997; 92:2203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/35\">",
"      Arora S, Katkov W, Cooley J, et al. Methotrexate in Crohn's disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999; 46:1724.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/36\">",
"      Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn's disease. Cochrane Database Syst Rev 2005; :CD003459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/37\">",
"      Nathan DM, Iser JH, Gibson PR. A single center experience of methotrexate in the treatment of Crohn's disease and ulcerative colitis: a case for subcutaneous administration. J Gastroenterol Hepatol 2008; 23:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/38\">",
"      L&eacute;mann M, Zenjari T, Bouhnik Y, et al. Methotrexate in Crohn's disease: long-term efficacy and toxicity. Am J Gastroenterol 2000; 95:1730.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/39\">",
"      Chong RY, Hanauer SB, Cohen RD. Efficacy of parenteral methotrexate in refractory Crohn's disease. Aliment Pharmacol Ther 2001; 15:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/40\">",
"      Dom&egrave;nech E, Ma&ntilde;osa M, Navarro M, et al. Long-term methotrexate for Crohn's disease: safety and efficacy in clinical practice. J Clin Gastroenterol 2008; 42:395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/41\">",
"      Din S, Dahele A, Fennel J, et al. Use of methotrexate in refractory Crohn's disease: the Edinburgh experience. Inflamm Bowel Dis 2008; 14:756.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/42\">",
"      Feagan BG, Fedorak RN, Irvine EJ, et al. A comparison of methotrexate with placebo for the maintenance of remission in Crohn's disease. North American Crohn's Study Group Investigators. N Engl J Med 2000; 342:1627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/43\">",
"      Patel V, Macdonald JK, McDonald JW, Chande N. Methotrexate for maintenance of remission in Crohn's disease. Cochrane Database Syst Rev 2009; :CD006884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/44\">",
"      Hausmann J, Zabel K, Herrmann E, Schr&ouml;der O. Methotrexate for maintenance of remission in chronic active Crohn's disease: long-term single-center experience and meta-analysis of observational studies. Inflamm Bowel Dis 2010; 16:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/45\">",
"      Te HS, Schiano TD, Kuan SF, et al. Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000; 95:3150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/46\">",
"      Brynskov J, Freund L, Rasmussen SN, et al. A placebo-controlled, double-blind, randomized trial of cyclosporine therapy in active chronic Crohn's disease. N Engl J Med 1989; 321:845.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/47\">",
"      Stange EF, Modigliani R, Pe&ntilde;a AS, et al. European trial of cyclosporine in chronic active Crohn's disease: a 12-month study. The European Study Group. Gastroenterology 1995; 109:774.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/48\">",
"      Jewell D, Lennard-Jones J, Cyclosporine Study Group of Great Britain and Ireland. Oral cyclosporine for chronic active Crohn's disease: A multicentre controlled trial. Eur J Gastroenterol Hepatol 1994; 6:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/49\">",
"      Feagan BG, McDonald JW, Rochon J, et al. Low-dose cyclosporine for the treatment of Crohn's disease. The Canadian Crohn's Relapse Prevention Trial Investigators. N Engl J Med 1994; 330:1846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/50\">",
"      McDonald JW, Feagan BG, Jewell D, et al. Cyclosporine for induction of remission in Crohn's disease. Cochrane Database Syst Rev 2005; :CD000297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/51\">",
"      Lazarev M, Present DH, Lichtiger S, et al. The effect of intravenous cyclosporine on rates of colonic surgery in hospitalized patients with severe Crohn's colitis. J Clin Gastroenterol 2012; 46:764.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/52\">",
"      Egan LJ, Sandborn WJ, Tremaine WJ. Clinical outcome following treatment of refractory inflammatory and fistulizing Crohn's disease with intravenous cyclosporine. Am J Gastroenterol 1998; 93:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/53\">",
"      Santos JV, Baudet JA, Casellas FJ, et al. Intravenous cyclosporine for steroid-refractory attacks of Crohn's disease. Short- and long-term results. J Clin Gastroenterol 1995; 20:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/54\">",
"      Hanauer SB, Smith MB. Rapid closure of Crohn's disease fistulas with continuous intravenous cyclosporin A. Am J Gastroenterol 1993; 88:646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/55\">",
"      Present DH, Lichtiger S. Efficacy of cyclosporine in treatment of fistula of Crohn's disease. Dig Dis Sci 1994; 39:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/56\">",
"      Banks PA, Present DH. Is there any value in using cyclosporine in the treatment of Crohn's disease-to use or not to use? Inflamm Bowel Dis 1995; 1:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/57\">",
"      Sandborn WJ. A critical review of cyclosporine therapy in inflammatory bowel disease. Inflamm Bowel Dis 1995; 1:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/58\">",
"      Sandborn WJ. Preliminary report on the use of oral tacrolimus (FK506) in the treatment of complicated proximal small bowel and fistulizing Crohn's disease. Am J Gastroenterol 1997; 92:876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/59\">",
"      van Dieren JM, Kuipers EJ, Samsom JN, et al. Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 2006; 12:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/60\">",
"      Baumgart DC, Pintoffl JP, Sturm A, et al. Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease--a long-term follow-up. Am J Gastroenterol 2006; 101:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/61\">",
"      Ierardi E, Principi M, Francavilla R, et al. Oral tacrolimus long-term therapy in patients with Crohn's disease and steroid resistance. Aliment Pharmacol Ther 2001; 15:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/62\">",
"      Ng SC, Arebi N, Kamm MA. Medium-term results of oral tacrolimus treatment in refractory inflammatory bowel disease. Inflamm Bowel Dis 2007; 13:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/63\">",
"      Benson A, Barrett T, Sparberg M, Buchman AL. Efficacy and safety of tacrolimus in refractory ulcerative colitis and Crohn's disease: a single-center experience. Inflamm Bowel Dis 2008; 14:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/64\">",
"      Ierardi E, Principi M, Rendina M, et al. Oral tacrolimus (FK 506) in Crohn's disease complicated by fistulae of the perineum. J Clin Gastroenterol 2000; 30:200.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/65\">",
"      Gonz&aacute;lez-Lama Y, Abreu L, Vera MI, et al. Long-term oral tacrolimus therapy in refractory to infliximab fistulizing Crohn's disease: a pilot study. Inflamm Bowel Dis 2005; 11:8.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/66\">",
"      Sandborn WJ, Present DH, Isaacs KL, et al. Tacrolimus for the treatment of fistulas in patients with Crohn's disease: a randomized, placebo-controlled trial. Gastroenterology 2003; 125:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/67\">",
"      Massey DC, Bredin F, Parkes M. Use of sirolimus (rapamycin) to treat refractory Crohn's disease. Gut 2008; 57:1294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7673/abstract/68\">",
"      Reinisch W, Pan&eacute;s J, L&eacute;mann M, et al. A multicenter, randomized, double-blind trial of everolimus versus azathioprine and placebo to maintain steroid-induced remission in patients with moderate-to-severe active Crohn's disease. Am J Gastroenterol 2008; 103:2284.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4081 Version 12.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0505-91.202.164.29-B6FAD70B64-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7673=[""].join("\n");
var outline_f7_31_7673=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H22\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      AZATHIOPRINE AND 6-MERCAPTOPURINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179162757\">",
"      Efficacy of AZA and 6-MP",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H179164795\">",
"      - Induction of remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Maintenance of remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Prevention of recurrence following surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Steroid sparing agent",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Fistula treatment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22270073\">",
"      Efficacy of AZA and 6-MP in combination with anti-TNF therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      METHOTREXATE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179164881\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Induction of remission",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Maintenance of remission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      CYCLOSPORINE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179164896\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179164889\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TACROLIMUS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179164910\">",
"      Efficacy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H179164917\">",
"      Toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SIROLIMUS AND EVEROLIMUS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      ANTI-TNF THERAPIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29559?source=related_link\">",
"      Adalimumab for treatment of Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/5/21592?source=related_link\">",
"      Azathioprine and 6-mercaptopurine in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/18/22823?source=related_link\">",
"      Glossary of common biostatistical and epidemiological terms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/24/32134?source=related_link\">",
"      Hepatotoxicity associated with chronic oral methotrexate for nonmalignant disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/34/17962?source=related_link\">",
"      Investigational therapies in the medical management of Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/61/11223?source=related_link\">",
"      Major side effects of low-dose methotrexate",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/50/809?source=related_link\">",
"      Medical prophylaxis of postoperative Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/63/10232?source=related_link\">",
"      Pharmacology and side effects of azathioprine when used in rheumatic diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/27/28090?source=related_link\">",
"      Pharmacology and side effects of cyclosporine and tacrolimus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20344?source=related_link\">",
"      Sulfasalazine and 5-aminosalicylates in the treatment of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/26/32169?source=related_link\">",
"      Use of methotrexate in the treatment of rheumatoid arthritis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_31_7674="Ventricular arrhythmias during pregnancy";
var content_f7_31_7674=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Ventricular arrhythmias during pregnancy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7674/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7674/contributors\">",
"     Louise Harris, MBChB",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7674/contributors\">",
"     Sing-Chien Yap, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7674/contributors\">",
"     Candice Silversides, MD, MS, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7674/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7674/contributors\">",
"     Hugh Calkins, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7674/contributors\">",
"     Heidi M Connolly, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/31/7674/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/31/7674/contributors\">",
"     Susan B Yeon, MD, JD, FACC",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/31/7674/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Oct 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H18809350\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arrhythmias are the most common cardiac complication encountered during pregnancy in women with and without structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. Arrhythmias may manifest for the first time during pregnancy or pregnancy can trigger exacerbations in women with known preexisting arrhythmias [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/1,4-6\">",
"     1,4-6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence, clinical presentation and management of ventricular arrhythmias will be reviewed. Cardiac arrest during pregnancy, general management of ventricular arrhythmias and cardiac arrest, electrocardiographic characteristics of ventricular arrhythmias and issues relating to supraventricular arrhythmias during pregnancy are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20840?source=see_link\">",
"     \"Management of cardiopulmonary arrest in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=see_link\">",
"     \"Approach to the diagnosis and treatment of wide QRS complex tachycardias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=see_link\">",
"     \"Advanced cardiac life support (ACLS) in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=see_link\">",
"     \"ECG tutorial: Ventricular arrhythmias\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=see_link\">",
"     \"Supraventricular arrhythmias during pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15918746\">",
"    <span class=\"h1\">",
"     GENERAL APPROACH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with established arrhythmias or structural heart disease are at highest risk of developing arrhythmias during pregnancy. Due to surgical advances, the number of women of childbearing age with congenital heart disease has increased and this group of women is at particularly high risk for arrhythmias (",
"    <a class=\"graphic graphic_figure graphicRef61986 \" href=\"UTD.htm?8/11/8382\">",
"     figure 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/1,2,7-11\">",
"     1,2,7-11",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    .) Since arrhythmias are frequently associated with acquired or structural heart disease, any woman who presents with an arrhythmia during pregnancy should undergo clinical evaluation for structural heart disease (including an electrocardiogram and a transthoracic echocardiogram). (See",
"    <a class=\"local\" href=\"#H18807931\">",
"     'VT in women with structural heart disease'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    In general, the approach to the treatment of arrhythmias in pregnancy is similar to that in the non-pregnant patient. However, due to the theoretical or known adverse effects of antiarrhythmic drugs on the fetus, antiarrhythmic drugs are generally reserved for the treatment of arrhythmias associated with significant symptoms or hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. Treatment strategies during pregnancy are hampered by the lack of randomized trials in this cohort of women. Choice of therapy, for the most part, is based on limited data from animal studies, case reports, observational studies, and clinical experience.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809358\">",
"    <span class=\"h1\">",
"     MECHANISM OF ARRHYTHMOGENESIS IN PREGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The exact mechanism of increased arrhythmia burden during pregnancy is unclear, but has been attributed to hemodynamic, hormonal, and autonomic changes related to pregnancy.",
"   </p>",
"   <p>",
"    The hemodynamic changes of pregnancy have been well studied and these changes likely contribute to the development of arrhythmias during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. Intravascular volume increases, augmenting the preload on the ventricles, and increasing both atrial and ventricular size [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/15,17-20\">",
"     15,17-20",
"    </a>",
"    ]. Atrial and ventricular myocardial stretch may contribute to arrhythmogenesis due to stretch-activated ion channel activity causing membrane depolarization, shortened refractoriness, slowed conduction and spatial dispersion of refractoriness and conduction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/21-24\">",
"     21-24",
"    </a>",
"    ]. There is also an increase in resting heart rate which has been associated with markers of arrhythmogenesis such as late potentials, premature ventricular contractions, and depressed heart rate variability [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/25\">",
"     25",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Few studies have been published on the influence of hormonal and autonomic changes on arrhythmogenesis in pregnancy. Although catecholamine levels do not appear to change during pregnancy, there is an increase in adrenergic responsiveness during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/26-30\">",
"     26-30",
"    </a>",
"    ]. Estrogen has been shown to increase the number of myocardial alpha-adrenergic receptors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/31\">",
"     31",
"    </a>",
"    ]. This increased adrenergic activity may contribute to enhanced automaticity and triggered activity [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=see_link\">",
"     \"Enhanced cardiac automaticity\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809366\">",
"    <span class=\"h1\">",
"     PALPITATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpitations occur frequently during pregnancy and are a common indication for cardiac evaluation during pregnancy. The differential diagnosis of palpitations is extensive and the diagnostic evaluation of pregnant women with palpitations does not differ from nonpregnant women. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=see_link\">",
"     \"Overview of palpitations in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One study compared 110 pregnant women with symptoms suggestive of possible arrhythmia (palpitations: 87 percent; dizziness: 13 percent;",
"    <span class=\"nowrap\">",
"     syncope/presyncope:",
"    </span>",
"    6 percent) with 52 pregnant women evaluated for an asymptomatic functional murmur [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/33\">",
"     33",
"    </a>",
"    ]. Prevalence of supraventricular and ventricular ectopic activity on 24-hour Holter ambulatory monitoring was similar in the symptomatic and control groups.",
"   </p>",
"   <p>",
"    Only 10 percent of symptomatic episodes were accompanied by the presence of an arrhythmia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/33\">",
"     33",
"    </a>",
"    ]. A sensation of palpitations during pregnancy in the absence of concomitant cardiac arrhythmias may be related to the high output state, including increased heart rate, decreased peripheral resistance, and increased stroke volumes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=see_link\">",
"     \"Maternal cardiovascular and hemodynamic adaptations to pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809374\">",
"    <span class=\"h1\">",
"     VENTRICULAR PREMATURE BEATS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular premature beats (VPBs) are frequently detected in pregnant women. The prevalence is dependent upon the duration of observation and the clinical presentation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9320?source=see_link\">",
"     \"Prevalence and evaluation of ventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In the above referenced study of 110 symptomatic and 52 asymptomatic pregnant women, the prevalence of isolated VPBs was similar in symptomatic and asymptomatic women (49 versus 40 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/33\">",
"     33",
"    </a>",
"    ]. However, frequent VPBs (&ge;50 VPBs per 24 hours) were more common in symptomatic women (22 versus 4 percent). There was a significant reduction in the frequency of combined atrial and ventricular ectopic activity in the 9 women in whom Holter monitoring was repeated postpartum.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809382\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;VPBs produce few or no symptoms in the majority of women, although some women may experience symptoms of palpitations or dizziness. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link\">",
"     \"Clinical significance and treatment of ventricular premature beats\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809390\">",
"    <span class=\"h2\">",
"     Management during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;No therapy is required for VPBs in asymptomatic patients. Pregnant women with symptomatic VPBs should be reassured of the benign nature of VPBs.",
"   </p>",
"   <p>",
"    Some experts counsel patients with palpitations to discontinue potential precipitant factors such as smoking, coffee intake, alcohol intake, and other stimulants [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/14\">",
"     14",
"    </a>",
"    ]. However the role of caffeine restriction has not been established. Moderate caffeine exposure has not been demonstrated to increase VPBs in patients with or without structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/34,35\">",
"     34,35",
"    </a>",
"    ], and caffeine restriction was not found to improve symptoms or reduce the frequency of VPBs in a small trial [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If ectopic activity continues and is associated with intolerable symptoms, beta blockers can be used.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     Metoprolol",
"    </a>",
"    is a preferred beta blocker in pregnant women since",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/46/30440?source=see_link\">",
"     atenolol",
"    </a>",
"    may impair fetal growth. The limited options for treatment of VPBs are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=see_link&amp;anchor=H12#H12\">",
"     \"Clinical significance and treatment of ventricular premature beats\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809398\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY OF VT AND VF",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ventricular tachyarrhythmias (ventricular tachycardia [VT] or ventricular fibrillation [VF]) are rare during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/37\">",
"     37",
"    </a>",
"    ]. VT has been reported in pregnant women without apparent structural heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/38-40\">",
"     38-40",
"    </a>",
"    ], but is usually associated with structural heart disease. The risk of recurrent VT during pregnancy is particularly high (27 percent) in women with structural heart disease and a history of VT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/6\">",
"     6",
"    </a>",
"    ]. Types of structural heart disease associated with VT in pregnancy include hypertrophic cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/1,6,41,42\">",
"     1,6,41,42",
"    </a>",
"    ], peripartum cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], arrhythmogenic right ventricular cardiomyopathy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/45\">",
"     45",
"    </a>",
"    ], congenital heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/1,6,46-48\">",
"     1,6,46-48",
"    </a>",
"    ], and valvular heart disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/1\">",
"     1",
"    </a>",
"    ]. Myocardial infarction with or without coronary artery disease has been observed during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/49-54\">",
"     49-54",
"    </a>",
"    ] and may be complicated by VT or VF [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Women with primary electrical diseases such as long QT syndrome (LQTS) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/55,56\">",
"     55,56",
"    </a>",
"    ] and Brugada syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/57\">",
"     57",
"    </a>",
"    ] are also at risk of VT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\", section on 'Pregnancy and delivery'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=see_link\">",
"     \"Peripartum cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: Specific lesions\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=see_link\">",
"     \"Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=see_link\">",
"     \"Brugada syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=see_link\">",
"     \"Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other medical conditions associated with ventricular tachycardia (VT) during pregnancy are hypomagnesemia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/58-60\">",
"     58-60",
"    </a>",
"    ], hypertensive crises [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/61,62\">",
"     61,62",
"    </a>",
"    ], and thyrotoxicosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/63\">",
"     63",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16085?source=see_link\">",
"     \"Significance of hypomagnesemia in cardiovascular disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=see_link\">",
"     \"Gestational hypertension\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=see_link\">",
"     \"Overview of thyroid disease in pregnancy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=see_link\">",
"     \"Cardiovascular effects of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The management of ventricular arrhythmias needs to be tailored to the individual. The following are among the clinical factors that should be considered:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Presence and severity of underlying heart disease",
"     </li>",
"     <li>",
"      Ventricular function",
"     </li>",
"     <li>",
"      Etiology of the VT (catecholamine sensitive versus noncatecholamine sensitive)",
"     </li>",
"     <li>",
"      Frequency and duration of VT (nonsustained versus sustained)",
"     </li>",
"     <li>",
"      Severity of associated symptoms",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following section will review issues regarding VT during pregnancy in women with and without structural heart disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809414\">",
"    <span class=\"h1\">",
"     IDIOPATHIC VT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monomorphic VT without apparent structural heart disease is considered idiopathic. The most common type of idiopathic VT is repetitive monomorphic VT which usually originates from the right ventricular outflow tract (ECG \"signature\": left bundle branch block and inferior axis) or, less often, from the left ventricular outflow tract (ECG pattern: right bundle branch block and inferior axis",
"    <strong>",
"     or",
"    </strong>",
"    left bundle and inferior axis but earlier precordial transition than for right ventricular outflow tract tachycardia). Another type is idiopathic left ventricular tachycardia which originates from the inferior aspect of the midseptum and has the morphologic pattern of right bundle branch block with left axis deviation (QRS axis around -60&deg;). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link\">",
"     \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=see_link\">",
"     \"Nonsustained VT in the absence of apparent structural heart disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A study of seven women presenting with new-onset idiopathic VT during pregnancy found that the VT was often catecholamine sensitive and that the VT was often suppressed in women who received beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/39\">",
"     39",
"    </a>",
"    ]. There were no maternal or fetal complications in this series. There is one case report of sudden death in a woman with idiopathic VT who died in the third trimester, three weeks after initiation of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/64\">",
"     64",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809422\">",
"    <span class=\"h2\">",
"     Management during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Idiopathic VT rarely degenerates into an unstable rhythm and usually has a benign prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/39,65\">",
"     39,65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Treatment of repetitive monomorphic VT with cardioselective beta blockers may be effective in pregnant women with idiopathic VT even in the absence of a clear relationship to adrenergic tone [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/39,65-69\">",
"       39,65-69",
"      </a>",
"      ].",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"       Sotalol",
"      </a>",
"      can be used as an alternative [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/70\">",
"       70",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link&amp;anchor=H18#H18\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'Treatment of RMVT'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      The less common idiopathic left ventricular tachycardia appears to respond well to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      , both for the termination of acute episodes and the prevention of recurrences [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/71,72\">",
"       71,72",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=see_link&amp;anchor=H27#H27\">",
"       \"Monomorphic ventricular tachycardia in the absence of apparent structural heart disease\", section on 'Treatment of ILVT'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809430\">",
"    <span class=\"h1\">",
"     LONG QT SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although VT during pregnancy has been reported in women with long QT syndrome (LQTS) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/73\">",
"     73",
"    </a>",
"    ], the increase in heart rate seen during pregnancy may serve to shorten the QT interval and therefore may be partially protective. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link\">",
"     \"Clinical features of congenital long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In women with LQTS, the risk of VT is especially high in the postpartum period [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/56\">",
"     56",
"    </a>",
"    ]. Increased risk of VT during the postpartum period may be related to a decrease in the heart rate and an associated increase in the QT interval. The physiologic stress and altered sleep patterns associated with caring for a newborn infant may also contribute to an increase in adrenergically mediated cardiac events.",
"   </p>",
"   <p>",
"    The effect of pregnancy was evaluated in a retrospective analysis of 422 women (111 probands and 311 first-degree relatives) entered into the International LQTS registry [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/56\">",
"     56",
"    </a>",
"    ]. Most of the probands had a personal history of syncope or aborted cardiac arrest. The following findings were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Probands were significantly more likely to have cardiac events (syncope, aborted cardiac arrest, or SCD) in the 40-week postpartum interval than during the prepregnancy period of 40 weeks (23.4 versus 3.8 percent). The increase in risk was distributed throughout the postpartum period. The incidence of first cardiac events during pregnancy was slightly but not significantly increased compared to the prepregnancy period (9.0 versus 3.8 percent)",
"     </li>",
"     <li>",
"      The postpartum increase in risk also applied to first cardiac events (9.0 versus 1.8 and 0 percent during and before pregnancy).",
"     </li>",
"     <li>",
"      Treatment with beta blockers was independently associated with a decrease in risk for cardiac events in probands during all three intervals (odds ratio 0.023).",
"     </li>",
"     <li>",
"      The average probability of having a cardiac event during the postpartum period in probands was 2 percent (one in 50 pregnancies). Treatment with a beta blocker lowered the risk to one in 2500 pregnancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The risks associated with pregnancy may be different among various LQTS genotypes. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=see_link&amp;anchor=H11#H11\">",
"     \"Clinical features of congenital long QT syndrome\", section on 'Influence of genotype'",
"    </a>",
"    .) The influence of genotype is illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a series of 388 LQTS patients referred for genetic testing, postpartum cardiac events were more commonly reported in patients with LQT2 mutation (13 of 80, 16 percent) than in patients with LQT1 (1 of 103, &lt;1 percent). [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/74\">",
"       74",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a series limited to women with a single LQT1 mutation, cardiac event rates associated with pregnancy were low (2.6 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/75\">",
"       75",
"      </a>",
"      ]. These events occurred only in women with a prior history of symptoms who were not taking beta blockers.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809438\">",
"    <span class=\"h2\">",
"     Management during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We agree with the 2006 American College of",
"    <span class=\"nowrap\">",
"     Cardiology/American",
"    </span>",
"    Heart",
"    <span class=\"nowrap\">",
"     Association/European",
"    </span>",
"    Society of Cardiology",
"    <span class=\"nowrap\">",
"     (ACC/AHA/ESC)",
"    </span>",
"    guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death and the 2011 European Society of Cardiology guidelines on the management of cardiovascular diseases during pregnancy. The guidelines recommended that pregnant women with LQTS who have had symptoms benefit from continued beta-blocker therapy throughout pregnancy and postpartum, unless there are definite contraindications [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/70,76\">",
"     70,76",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18807931\">",
"    <span class=\"h1\">",
"     VT IN WOMEN WITH STRUCTURAL HEART DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809446\">",
"    <span class=\"h2\">",
"     Hypertrophic cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;In general, women with hypertrophic cardiomyopathy (HCM) tolerate pregnancy well [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/42,77\">",
"     42,77",
"    </a>",
"    ], although several case reports have described cardiac complications and sudden death during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/41,42,78-80\">",
"     41,42,78-80",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=see_link\">",
"     \"Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\", section on 'Pregnancy and delivery'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The largest study investigating mortality and morbidity in pregnant women with HCM included 100 women who had a total of 199 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/42\">",
"     42",
"    </a>",
"    ]. Two sudden cardiac deaths occurred during pregnancy in women with high risk features. One of the women had severe left ventricular hypertrophy (30 mm maximal wall thickness) and a resting outflow gradient of 115 mmHg. She died suddenly four days after delivery after complaining of palpitations. The other woman had a family history of eight deaths in young relatives, five of which were sudden. This patient developed recurrent episodes of sustained VT during labor.",
"   </p>",
"   <p>",
"    Management of pregnancy and delivery in women with HCM is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=see_link&amp;anchor=H7#H7\">",
"     \"Overview of hypertrophic cardiomyopathy management including treatment of special problems\", section on 'Pregnancy and delivery'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809454\">",
"    <span class=\"h2\">",
"     Congenital heart disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prevalence of sustained VT during pregnancy in women with CHD has been reported to range from 4.5 to 15.9 per 1,000 pregnancies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/1,46\">",
"     1,46",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: General principles\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=see_link\">",
"     \"Pregnancy in women with congenital heart disease: Specific lesions\"",
"    </a>",
"    .) Prevalence rates are strongly influenced by the types of cardiac lesions in the study population.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large prospective multicenter study in women with CHD, two cases of sustained VT occurred in 445 pregnancies. One woman had an unrepaired intracardiac shunt and the other had repaired congenital aortic stenosis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A multicenter study from Japan reported two cases of sustained VT during 126 pregnancies [",
"      <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/46\">",
"       46",
"      </a>",
"      ]. Both cases of VT occurred in women with repaired tetralogy of Fallot and both were successfully treated with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      . Seven pregnancies were complicated by nonsustained VT, none of which were treated.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809462\">",
"    <span class=\"h2\">",
"     Peripartum cardiomyopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Peripartum cardiomyopathy is a rare and sometimes life-threatening condition defined as development of systolic heart failure in the last month of pregnancy or within five months of delivery. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=see_link\">",
"     \"Peripartum cardiomyopathy\"",
"    </a>",
"    .) The incidence varies widely among various populations. The clinical presentation includes symptoms of new-onset heart failure such as dyspnea, cough, orthopnea, and hemoptysis. The prevalence of sustained VT in patients with peripartum cardiomyopathy is unknown; few cases have been reported in the literature [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/43,44,81\">",
"     43,44,81",
"    </a>",
"    ]. These ventricular arrhythmias can be refractory to pharmacologic treatment (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/31/39417?source=see_link\">",
"     metoprolol",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    ) and DC cardioversion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/43,44,81\">",
"     43,44,81",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18807997\">",
"    <span class=\"h1\">",
"     MANAGEMENT OF VT DURING PREGNANCY IN WOMEN WITH STRUCTURAL HEART DISEASE",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809470\">",
"    <span class=\"h2\">",
"     Management of acute episodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute treatment of sustained ventricular arrhythmias in pregnant women is similar to that in nonpregnant women. Ventricular arrhythmias in the presence of structural heart disease are potentially life-threatening and require immediate evaluation for hemodynamic instability to determine whether electrical cardioversion or defibrillation is indicated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/70,76\">",
"     70,76",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In hemodynamically well tolerated VT, pharmacological cardioversion may be acceptable. Pharmacological options include intravenous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/34/35360?source=see_link\">",
"     lidocaine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/70,76\">",
"     70,76",
"    </a>",
"    ]; the choice of pharmacological agents should be tailored to the individual case. For women at risk for VT during labor and delivery, it is important to ensure that appropriate cardiac medications and external defibrillators are available in the delivery suites.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809478\">",
"    <span class=\"h2\">",
"     Electrical cardioversion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Emergent or elective electrical cardioversion can be performed at all stages of pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/14,82-88\">",
"     14,82-88",
"    </a>",
"    ]. Electrical cardioversion is indicated for any sustained VT with hemodynamic compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/70,76\">",
"     70,76",
"    </a>",
"    ] and can be considered for drug-refractory VT. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=see_link\">",
"     \"Basic principles and technique of cardioversion and defibrillation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=see_link\">",
"     \"Cardioversion for specific arrhythmias\"",
"    </a>",
"    .) Electrical cardioversion does not result in compromise of blood flow to the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/89\">",
"     89",
"    </a>",
"    ]. While there is a theoretical risk of inducing an arrhythmia in the fetus, this risk is very small due to the high fibrillation threshold and small amount of energy reaching the fetus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/14,82,90\">",
"     14,82,90",
"    </a>",
"    ]. Nonetheless, fetal rhythm monitoring is recommended, because of rare reported cases of cardioversion precipitating fetal distress requiring emergency cesarean delivery [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/91\">",
"     91",
"    </a>",
"    ]. In the third trimester, some physicians prefer to perform electrical cardioversion under general anesthesia and intubation considering the more difficult airway and increased risk of gastric aspiration during pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809486\">",
"    <span class=\"h2\">",
"     Prophylactic pharmacologic therapy during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of recurrent VT and sudden death in women with structural heart disease can be substantial and the benefits of prophylactic drug therapy may outweigh the potential fetal adverse effects of these drugs. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=see_link\">",
"     \"Overview of sudden cardiac arrest and sudden cardiac death\"",
"    </a>",
"    .) The risk of sudden death is further increased when concomitant left ventricular dysfunction is present.",
"   </p>",
"   <p>",
"    Depending on the underlying cardiac condition, beta-1 selective beta-blockers alone,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?22/58/23466?source=see_link\">",
"     amiodarone",
"    </a>",
"    alone, or both in combination can be effective in preventing VT during pregnancy as noted in the 2006",
"    <span class=\"nowrap\">",
"     ACC/AHA/ESC",
"    </span>",
"    ventricular arrhythmia guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/70\">",
"     70",
"    </a>",
"    ]. Gestational exposure to amiodarone is associated with neonatal hypothyroidism and hyperthyroidism. Small-for-gestational-age infants are reported with gestational exposure to the combination of amiodarone and beta blockers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/92\">",
"     92",
"    </a>",
"    ]. In some cases,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/13/21721?source=see_link\">",
"     sotalol",
"    </a>",
"    can be considered if beta-blocker therapy is ineffective. Because of potential side effects, all women should be counseled about the potential risks and benefits of drug therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=see_link\">",
"     \"Major side effects of amiodarone\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=see_link\">",
"     \"Clinical uses of amiodarone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although some have used class IA (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/48/777?source=see_link\">",
"     quinidine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/34/36391?source=see_link\">",
"     procainamide",
"    </a>",
"    ) or IC (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/30/30182?source=see_link\">",
"     flecainide",
"    </a>",
"    ) drugs as prophylactic treatment for VT during pregnancy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/93,94\">",
"     93,94",
"    </a>",
"    ], these drugs are not generally recommended since they have",
"    <strong>",
"     not",
"    </strong>",
"    improved survival in the nonpregnant population with structural heart disease, presumably because of proarrhythmic effects [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/95\">",
"     95",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809494\">",
"    <span class=\"h2\">",
"     Implantable cardioverter-defibrillator",
"    </span>",
"    &nbsp;&mdash;&nbsp;Women with an implantable cardioverter-defibrillator (ICD) can have a successful pregnancy with good fetal outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/96,97\">",
"     96,97",
"    </a>",
"    ]. Indications for ICD placement are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=see_link\">",
"     \"Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=see_link\">",
"     \"Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a retrospective multicenter study of pregnancy outcomes in women with ICDs (n = 44), 25 percent (11 of 44) of the pregnancies were complicated by at least one shock [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/96\">",
"     96",
"    </a>",
"    ]. All ICDs were implanted for secondary prevention and the underlying cardiac diseases were primary electrical diseases (ie, LQTS, idiopathic ventricular fibrillation) or structural heart diseases (ie, cardiomyopathy, congenital heart disease, arrhythmogenic right ventricular dysplasia). Pregnancy was not associated with an increase in ICD-related complications or an increase in the number of shocks (0.07 versus 0.06 shocks per month) compared to the preconception period [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/96\">",
"     96",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The experience with ICD implantation during pregnancy is limited [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/98\">",
"     98",
"    </a>",
"    ], however, pacemaker implantation during pregnancy can be accomplished and total radiation dose can be reduced by using echocardiographic guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/99,100\">",
"     99,100",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If a pregnant patient is determined to be at high risk of sudden death, placement of an implantable defibrillator is generally deferred until after delivery of the baby. In this setting, an external wearable automatic defibrillator (LifeVest) is often prescribed for the duration of the pregnancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18809502\">",
"    <span class=\"h2\">",
"     Radiofrequency catheter ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The success rate of radiofrequency catheter ablation of monomorphic VT is between 80 to 100 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/101-105\">",
"     101-105",
"    </a>",
"    ] and may be considered in women who are using antiarrhythmic therapy and are contemplating pregnancy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=see_link\">",
"     \"Catheter ablation for ventricular arrhythmias\"",
"    </a>",
"    .) Currently, there are no reported cases of catheter ablation of VT during pregnancy.",
"   </p>",
"   <p>",
"    Experience with radiofrequency catheter ablation during pregnancy has been limited to cases of SVT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/106-113\">",
"     106-113",
"    </a>",
"    ]. These procedures are generally not performed during pregnancy, mainly due to concerns of ionizing radiation exposure to the fetus. However, in rare cases, women with severe and drug-resistant VT during pregnancy may be considered for an ablation procedure. The risk of radiation exposure for the fetus during a typical ablation is small (&lt;1 mGy at all periods of gestation), and is mainly attributable to scatter from the thorax of the mother [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/114\">",
"     114",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=see_link&amp;anchor=H3#H3\">",
"     \"Diagnostic imaging procedures during pregnancy\", section on 'Effects of ionizing radiation on the fetus'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18808159\">",
"    <span class=\"h1\">",
"     ISSUES REGARDING ANTIARRHYTHMIC DRUG TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Use of antiarrhythmic drugs in pregnancy requires attention to potential alterations in pharmacokinetics as well as fetal risk. For most antiarrhythmic drugs, adequate and well-controlled studies in pregnant women are lacking and most drugs are categorized as class C drugs by the US Food and Drug Administration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/31/7674/abstract/115,116\">",
"     115,116",
"    </a>",
"    ] (",
"    <a class=\"graphic graphic_table graphicRef50021 \" href=\"UTD.htm?16/42/17068\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_table graphicRef50716 \" href=\"UTD.htm?8/35/8765\">",
"     table 2",
"    </a>",
"    ). Another consideration is potential adverse effects in the infant during breast feeding (",
"    <a class=\"graphic graphic_table graphicRef50716 \" href=\"UTD.htm?8/35/8765\">",
"     table 2",
"    </a>",
"    ). Antiarrhythmic drug safety during pregnancy, teratogenic risk, pharmacokinetic changes and breast feeding are discussed further separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=see_link&amp;anchor=H11407891#H11407891\">",
"     \"Supraventricular arrhythmias during pregnancy\", section on 'Issues regarding antiarrhythmic drug treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1633095\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ventricular tachyarrhythmias are frequently associated with acquired or structural heart disease and therefore any woman who presents with a ventricular arrhythmia during pregnancy should undergo clinical evaluation for structural heart disease (including an electrocardiogram and a transthoracic echocardiogram). (See",
"      <a class=\"local\" href=\"#H15918746\">",
"       'General approach'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18807931\">",
"       'VT in women with structural heart disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Monomorphic ventricular tachycardia without apparent structural heart disease is considered idiopathic. The most common type originates from the right ventricular outflow tract, and this form of ventricular tachycardia can often be successfully treated with beta blockers or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"       verapamil",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H18809414\">",
"       'Idiopathic VT'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with the long QT syndrome are at risk for ventricular tachycardia, especially in the postpartum period. Pregnant women with long QT syndrome should be treated with beta-blocker therapy throughout pregnancy and postpartum. (See",
"      <a class=\"local\" href=\"#H18809430\">",
"       'Long QT syndrome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Acute treatment of sustained ventricular arrhythmias in pregnant women is similar to that in nonpregnant women. Ventricular arrhythmias in the presence of structural heart disease are potentially life-threatening and require immediate evaluation for hemodynamic instability to determine whether electrical cardioversion or defibrillation is indicated. (See",
"      <a class=\"local\" href=\"#H18809470\">",
"       'Management of acute episodes'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In women with structural heart disease and a history of ventricular tachycardia, the benefits of prophylactic drug therapy may outweigh the potential fetal adverse effects of these drugs. (See",
"      <a class=\"local\" href=\"#H18809486\">",
"       'Prophylactic pharmacologic therapy during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Women with an implantable cardioverter-defibrillator can have a successful pregnancy with good fetal outcome. (See",
"      <a class=\"local\" href=\"#H18809494\">",
"       'Implantable cardioverter-defibrillator'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Information on the use of specific antiarrhythmic drugs in pregnancy, including the FDA risk category and pregnancy implications, is available in the UpToDate drug database. (See",
"      <a class=\"local\" href=\"#H18808159\">",
"       'Issues regarding antiarrhythmic drug treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/1\">",
"      Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/2\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/3\">",
"      Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010; 31:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/4\">",
"      Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 1995; 76:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/5\">",
"      Doig JC, McComb JM, Reid DS. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 1992; 67:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/6\">",
"      Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006; 97:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/7\">",
"      Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997; 96:2789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/8\">",
"      Drenthen W, Pieper PG, Ploeg M, et al. Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. Eur Heart J 2005; 26:2588.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/9\">",
"      Drenthen W, Pieper PG, van der Tuuk K, et al. Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. Eur Heart J 2005; 26:2581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/10\">",
"      Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Pregnancy and delivery in women after Fontan palliation. Heart 2006; 92:1290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/11\">",
"      Blomstr&ouml;m-Lundqvist C, Scheinman MM, Aliot EM, et al. ACC/AHA/ESC guidelines for the management of patients with supraventricular arrhythmias--executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Supraventricular Arrhythmias). Circulation 2003; 108:1871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/12\">",
"      Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf 1999; 20:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/13\">",
"      Task Force on the Management of Cardiovascular Diseases During Pregnancy of the European Society of Cardiology. Expert consensus document on management of cardiovascular diseases during pregnancy. Eur Heart J 2003; 24:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/14\">",
"      Cox JL, Gardner MJ. Treatment of cardiac arrhythmias during pregnancy. Prog Cardiovasc Dis 1993; 36:137.",
"     </a>",
"    </li>",
"    <li>",
"     Silversides CK, Colman JM. Physiological changes in pregnancy. In: Heart disease in pregnancy, 2nd ed, Oakley C, Warnes CA (Eds), Blackwell Publishing, Malden 2007. p.6.",
"    </li>",
"    <li>",
"     Elkayam U, Gleicher N. Hemodynamics and cardiac function during normal pregnancy and puerperium. In: Cardiac problems in pregnancy, 3rd ed, Elkayam U, Gleicher N (Eds), Wiley-Liss, New York 1998. p.3.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/17\">",
"      Katz R, Karliner JS, Resnik R. Effects of a natural volume overload state (pregnancy) on left ventricular performance in normal human subjects. Circulation 1978; 58:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/18\">",
"      Rubler S, Damani PM, Pinto ER. Cardiac size and performance during pregnancy estimated with echocardiography. Am J Cardiol 1977; 40:534.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/19\">",
"      Liebson PR, Mann LI, Evans MI, et al. Cardiac performance during pregnancy: serial evaluation using external systolic time intervals. Am J Obstet Gynecol 1975; 122:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/20\">",
"      Campos O. Doppler Echocardiography During Pregnancy: Physiological and Abnormal Findings. Echocardiography 1996; 13:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/21\">",
"      Franz MR, Cima R, Wang D, et al. Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias. Circulation 1992; 86:968.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/22\">",
"      Wang Y, Joyner RW, Wagner MB, et al. Stretch-activated channel activation promotes early afterdepolarizations in rat ventricular myocytes under oxidative stress. Am J Physiol Heart Circ Physiol 2009; 296:H1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/23\">",
"      Ninio DM, Saint DA. The role of stretch-activated channels in atrial fibrillation and the impact of intracellular acidosis. Prog Biophys Mol Biol 2008; 97:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/24\">",
"      Kamkin A, Kiseleva I, Isenberg G. Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 2000; 48:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/25\">",
"      Soliman EZ, Elsalam MA, Li Y. The relationship between high resting heart rate and ventricular arrhythmogenesis in patients referred to ambulatory 24 h electrocardiographic recording. Europace 2010; 12:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/26\">",
"      Zuspan FP. Catecholamines. Their role in pregnancy and the development of pregnancy-induced hypertension. J Reprod Med 1979; 23:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/27\">",
"      Natrajan PG, McGarrigle HH, Lawrence DM, Lachelin GC. Plasma noradrenaline and adrenaline levels in normal pregnancy and in pregnancy-induced hypertension. Br J Obstet Gynaecol 1982; 89:1041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/28\">",
"      Whittaker PG, Gerrard J, Lind T. Catecholamine responses to changes in posture during human pregnancy. Br J Obstet Gynaecol 1985; 92:586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/29\">",
"      Barron WM, Mujais SK, Zinaman M, et al. Plasma catecholamine responses to physiologic stimuli in normal human pregnancy. Am J Obstet Gynecol 1986; 154:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/30\">",
"      Ramsay MM, Broughton Pipkin F, Rubin PC. Pressor, heart rate and plasma catecholamine responses to noradrenaline in pregnant and nonpregnant women. Br J Obstet Gynaecol 1993; 100:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/31\">",
"      Roberts JM, Insel PA, Goldfien A. Regulation of myometrial adrenoreceptors and adrenergic response by sex steroids. Mol Pharmacol 1981; 20:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/32\">",
"      Priori SG, Mantica M, Schwartz PJ. Delayed afterdepolarizations elicited in vivo by left stellate ganglion stimulation. Circulation 1988; 78:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/33\">",
"      Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol 1997; 79:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/34\">",
"      Newcombe PF, Renton KW, Rautaharju PM, et al. High-dose caffeine and cardiac rate and rhythm in normal subjects. Chest 1988; 94:90.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/35\">",
"      Myers MG. Caffeine and cardiac arrhythmias. Ann Intern Med 1991; 114:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/36\">",
"      Newby DE, Neilson JM, Jarvie DR, Boon NA. Caffeine restriction has no role in the management of patients with symptomatic idiopathic ventricular premature beats. Heart 1996; 76:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/37\">",
"      Li JM, Nguyen C, Joglar JA, et al. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol 2008; 31:538.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/38\">",
"      PINE HL, FOX L, SHOOK DM. PAROXYSMAL VENTRICULAR TACHYCARDIA COMPLICATING PREGNANCY. Am J Cardiol 1965; 15:732.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/39\">",
"      Brodsky M, Doria R, Allen B, et al. New-onset ventricular tachycardia during pregnancy. Am Heart J 1992; 123:933.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/40\">",
"      Braverman AC, Bromley BS, Rutherford JD. New onset ventricular tachycardia during pregnancy. Int J Cardiol 1991; 33:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/41\">",
"      Shah DM, Sunderji SG. Hypertrophic cardiomyopathy and pregnancy: report of a maternal mortality and review of literature. Obstet Gynecol Surv 1985; 40:444.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/42\">",
"      Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40:1864.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/43\">",
"      Gemici G, Tezcan H, Fak AS, Oktay A. Peripartum cardiomyopathy presenting with repetitive monomorphic ventricular tachycardia. Pacing Clin Electrophysiol 2004; 27:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/44\">",
"      Puri A, Sethi R, Singh B, et al. Peripartum cardiomyopathy presenting with ventricular tachycardia: a rare presentation. Indian Pacing Electrophysiol J 2009; 9:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/45\">",
"      Bauce B, Daliento L, Frigo G, et al. Pregnancy in women with arrhythmogenic right ventricular cardiomyopathy/dysplasia. Eur J Obstet Gynecol Reprod Biol 2006; 127:186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/46\">",
"      Tateno S, Niwa K, Nakazawa M, et al. Arrhythmia and conduction disturbances in patients with congenital heart disease during pregnancy: multicenter study. Circ J 2003; 67:992.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/47\">",
"      Whittemore R, Hobbins JC, Engle MA. Pregnancy and its outcome in women with and without surgical treatment of congenital heart disease. Am J Cardiol 1982; 50:641.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/48\">",
"      Perloff JK. Pregnancy and congenital heart disease. J Am Coll Cardiol 1991; 18:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/49\">",
"      Sasse L, Wagner R, Murray FE. Transmural myocardial infarction during pregnancy. Am J Cardiol 1975; 35:448.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/50\">",
"      Sperry KL. Myocardial infarction in pregnancy. J Forensic Sci 1987; 32:1464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/51\">",
"      Hankins GD, Wendel GD Jr, Leveno KJ, Stoneham J. Myocardial infarction during pregnancy: a review. Obstet Gynecol 1985; 65:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/52\">",
"      Curry JJ, Quintana FJ. Myocardial infarction with ventricular fibrillation during pregnancy treated by direct current defibrillation with fetal survival. Chest 1970; 58:82.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/53\">",
"      O'Donnell M, Meecham J, Tosson SR, Ward S. Ventricular fibrillation and reinfarction in pregnancy. Postgrad Med J 1987; 63:1095.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/54\">",
"      Sonel A, Erol C, Oral D, et al. Acute myocardial infarction and normal coronary arteries in a pregnant woman. Cardiology 1988; 75:218.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/55\">",
"      Roden DM, Lazzara R, Rosen M, et al. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation 1996; 94:1996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/56\">",
"      Rashba EJ, Zareba W, Moss AJ, et al. Influence of pregnancy on the risk for cardiac events in patients with hereditary long QT syndrome. LQTS Investigators. Circulation 1998; 97:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/57\">",
"      Sharif-Kazemi MB, Emkanjoo Z, Tavoosi A, et al. Electrical storm in Brugada syndrome during pregnancy. Pacing Clin Electrophysiol 2011; 34:e18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/58\">",
"      Onagawa T, Ohkuchi A, Ohki R, et al. Woman with postpartum ventricular tachycardia and hypomagnesemia. J Obstet Gynaecol Res 2003; 29:92.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/59\">",
"      Varon ME, Sherer DM, Abramowicz JS, Akiyama T. Maternal ventricular tachycardia associated with hypomagnesemia. Am J Obstet Gynecol 1992; 167:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/60\">",
"      Mela T, Galvin JM, McGovern BA. Magnesium deficiency during lactation as a precipitant of ventricular tachyarrhythmias. Pacing Clin Electrophysiol 2002; 25:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/61\">",
"      Naidoo DP, Bhorat I, Moodley J, et al. Continuous electrocardiographic monitoring in hypertensive crises in pregnancy. Am J Obstet Gynecol 1991; 164:530.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/62\">",
"      Bhorat IE, Naidoo DP, Rout CC, Moodley J. Malignant ventricular arrhythmias in eclampsia: a comparison of labetalol with dihydralazine. Am J Obstet Gynecol 1993; 168:1292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/63\">",
"      Kinugawa T, Fujimoto Y, Miyakoda H, et al. A case of paroxysmal ventricular tachycardia during pregnancy. Jpn Circ J 1989; 53:807.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/64\">",
"      RALLY CR, WALTERS MB. Paroxysmal ventricular tachycardia without evident heart disease. Can Med Assoc J 1962; 86:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/65\">",
"      Lemery R, Brugada P, Bella PD, et al. Nonischemic ventricular tachycardia. Clinical course and long-term follow-up in patients without clinically overt heart disease. Circulation 1989; 79:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/66\">",
"      Page RL, Shenasa H, Evans JJ, et al. Radiofrequency catheter ablation of idiopathic recurrent ventricular tachycardia with right bundle branch block, left axis morphology. Pacing Clin Electrophysiol 1993; 16:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/67\">",
"      Trappe HJ, Brugada P, Talajic M, et al. Prognosis of patients with ventricular tachycardia and ventricular fibrillation: role of the underlying etiology. J Am Coll Cardiol 1988; 12:166.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/68\">",
"      Sung RJ, Keung EC, Nguyen NX, Huycke EC. Effects of beta-adrenergic blockade on verapamil-responsive and verapamil-irresponsive sustained ventricular tachycardias. J Clin Invest 1988; 81:688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/69\">",
"      Chandra NC, Gates EA, Thamer M. Conservative treatment of paroxysmal ventricular tachycardia during pregnancy. Clin Cardiol 1991; 14:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/70\">",
"      Zipes DP, Camm AJ, Borggrefe M, et al. ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (writing committee to develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 2006; 114:e385.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/71\">",
"      Lin FC, Finley CD, Rahimtoola SH, Wu D. Idiopathic paroxysmal ventricular tachycardia with a QRS pattern of right bundle branch block and left axis deviation: a unique clinical entity with specific properties. Am J Cardiol 1983; 52:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/72\">",
"      Cleary-Goldman J, Salva CR, Infeld JI, Robinson JN. Verapamil-sensitive idiopathic left ventricular tachycardia in pregnancy. J Matern Fetal Neonatal Med 2003; 14:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/73\">",
"      O'Callaghan AC, Normandale JP, Morgan M. The prolonged Q-T syndrome. A review with anaesthetic implications and a report of two cases. Anaesth Intensive Care 1982; 10:50.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/74\">",
"      Khositseth A, Tester DJ, Will ML, et al. Identification of a common genetic substrate underlying postpartum cardiac events in congenital long QT syndrome. Heart Rhythm 2004; 1:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/75\">",
"      Heradien MJ, Goosen A, Crotti L, et al. Does pregnancy increase cardiac risk for LQT1 patients with the KCNQ1-A341V mutation? J Am Coll Cardiol 2006; 48:1410.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/76\">",
"      European Society of Gynecology (ESG), Association for European Paediatric Cardiology (AEPC), German Society for Gender Medicine (DGesGM), et al. ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:3147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/77\">",
"      Oakley GD, McGarry K, Limb DG, Oakley CM. Management of pregnancy in patients with hypertrophic cardiomyopathy. Br Med J 1979; 1:1749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/78\">",
"      Pelliccia F, Cianfrocca C, Gaudio C, Reale A. Sudden death during pregnancy in hypertrophic cardiomyopathy. Eur Heart J 1992; 13:421.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/79\">",
"      van Kasteren YM, Kleinhout J, Smit MA, et al. Hypertrophic cardiomyopathy and pregnancy: a report of three cases. Eur J Obstet Gynecol Reprod Biol 1991; 38:63.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/80\">",
"      Tanous D, Siu SC, Mason J, et al. B-type natriuretic peptide in pregnant women with heart disease. J Am Coll Cardiol 2010; 56:1247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/81\">",
"      Palma EC, Saxenberg V, Vijayaraman P, et al. Histopathological correlation of ablation lesions guided by noncontact mapping in a patient with peripartum cardiomyopathy and ventricular tachycardia. Pacing Clin Electrophysiol 2001; 24:1812.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/82\">",
"      Page RL. Treatment of arrhythmias during pregnancy. Am Heart J 1995; 130:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/83\">",
"      Ueland K, McAnulty JH, Ueland FR, Metcalfe J. Special considerations in the use of cardiovascular drugs. Clin Obstet Gynecol 1981; 24:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/84\">",
"      VOGEL JH, PRYOR R, BLOUNT SG Jr. DIRECT-CURRENT DEFIBRILLATION DURING PREGNANCY. JAMA 1965; 193:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/85\">",
"      Schroeder JS, Harrison DC. Repeated cardioversion during pregnancy. Treatment of refractory paroxysmal atrial tachycardia during 3 successive pregnancies. Am J Cardiol 1971; 27:445.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/86\">",
"      Lee RV, Rodgers BD, White LM, Harvey RC. Cardiopulmonary resuscitation of pregnant women. Am J Med 1986; 81:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/87\">",
"      Hubbard WN, Jenkins BA, Ward DE. Persistent atrial tachycardia in pregnancy. Br Med J (Clin Res Ed) 1983; 287:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/88\">",
"      Russell RO Jr. Paroxysmal ventricular tachycardia associated with pregnancy. Ala J Med Sci 1969; 6:111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/89\">",
"      Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006; 126:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/90\">",
"      DeSilva RA, Graboys TB, Podrid PJ, Lown B. Cardioversion and defibrillation. Am Heart J 1980; 100:881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/91\">",
"      Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG 2002; 109:1406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/92\">",
"      Magee LA, Downar E, Sermer M, et al. Pregnancy outcome after gestational exposure to amiodarone in Canada. Am J Obstet Gynecol 1995; 172:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/93\">",
"      Connaughton M, Jenkins BS. Successful use of flecainide to treat new onset maternal ventricular tachycardia in pregnancy. Br Heart J 1994; 72:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/94\">",
"      Hill LM, Malkasian GD Jr. The use of quinidine sulfate throughout pregnancy. Obstet Gynecol 1979; 54:366.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/95\">",
"      Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/96\">",
"      Natale A, Davidson T, Geiger MJ, Newby K. Implantable cardioverter-defibrillators and pregnancy: a safe combination? Circulation 1997; 96:2808.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/97\">",
"      Piper JM, Berkus M, Ridgway LE 3rd. Pregnancy complicated by chronic cardiomyopathy and an automatic implantable cardioverter defibrillator. Am J Obstet Gynecol 1992; 167:506.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/98\">",
"      Abello M, Peinado R, Merino JL, et al. Cardioverter defibrillator implantation in a pregnant woman guided with transesophageal echocardiography. Pacing Clin Electrophysiol 2003; 26:1913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/99\">",
"      Jordaens LJ, Vandenbogaerde JF, Van de Bruaene P, De Buyzere M. Transesophageal echocardiography for insertion of a physiological pacemaker in early pregnancy. Pacing Clin Electrophysiol 1990; 13:955.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/100\">",
"      Lau CP, Lee CP, Wong CK, et al. Rate responsive pacing with a minute ventilation sensing pacemaker during pregnancy and delivery. Pacing Clin Electrophysiol 1990; 13:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/101\">",
"      Coggins DL, Lee RJ, Sweeney J, et al. Radiofrequency catheter ablation as a cure for idiopathic tachycardia of both left and right ventricular origin. J Am Coll Cardiol 1994; 23:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/102\">",
"      Klein LS, Shih HT, Hackett FK, et al. Radiofrequency catheter ablation of ventricular tachycardia in patients without structural heart disease. Circulation 1992; 85:1666.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/103\">",
"      Calkins H, Kalbfleisch SJ, el-Atassi R, et al. Relation between efficacy of radiofrequency catheter ablation and site of origin of idiopathic ventricular tachycardia. Am J Cardiol 1993; 71:827.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/104\">",
"      Timmermans C, Rodriguez LM, Crijns HJ, et al. Idiopathic left bundle-branch block-shaped ventricular tachycardia may originate above the pulmonary valve. Circulation 2003; 108:1960.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/105\">",
"      Rodriguez LM, Smeets JL, Timmermans C, Wellens HJ. Predictors for successful ablation of right- and left-sided idiopathic ventricular tachycardia. Am J Cardiol 1997; 79:309.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/106\">",
"      Pagad SV, Barmade AB, Toal SC, et al. 'Rescue' radiofrequency ablation for atrial tachycardia presenting as cardiomyopathy in pregnancy. Indian Heart J 2004; 56:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/107\">",
"      Bongiorni MG, Di Cori A, Soldati E, et al. Radiofrequency catheter ablation of atrioventricular nodal reciprocating tachycardia using intracardiac echocardiography in pregnancy. Europace 2008; 10:1018.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/108\">",
"      Risius T, Mortensen K, Meinertz T, Willems S. Cluster of multiple atrial tachycardias limited to pregnancy after radiofrequency ablation following senning operation. Int J Cardiol 2008; 123:e48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/109\">",
"      Kanjwal Y, Kosinski D, Kanj M, et al. Successful radiofrequency catheter ablation of left lateral accessory pathway using transseptal approach during pregnancy. J Interv Card Electrophysiol 2005; 13:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/110\">",
"      Bombelli F, Lagona F, Salvati A, et al. Radiofrequency catheter ablation in drug refractory maternal supraventricular tachycardias in advanced pregnancy. Obstet Gynecol 2003; 102:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/111\">",
"      Dom&iacute;nguez A, Iturralde P, Hermosillo AG, et al. Successful radiofrequency ablation of an accessory pathway during pregnancy. Pacing Clin Electrophysiol 1999; 22:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/112\">",
"      Berruezo A, D&iacute;ez GR, Berne P, et al. Low exposure radiation with conventional guided radiofrequency catheter ablation in pregnant women. Pacing Clin Electrophysiol 2007; 30:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/113\">",
"      Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol 2010; 21:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/31/7674/abstract/114\">",
"      Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation procedures. Circulation 2001; 104:893.",
"     </a>",
"    </li>",
"    <li>",
"     Leung CY, Brodsky MA. Cardiac arrhythmias and pregnancy. In: Cardiac problems in pregnancy, 3rd ed, Elkayam U, Gleicher N (Eds), Wiley-Liss, New York 1998. p.155.",
"    </li>",
"    <li>",
"     Briggs GC, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, Lippincott Williams &amp; Wilkins, Philadelphia 2005.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13601 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-27.109.116.13-DB94331016-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7674=[""].join("\n");
var outline_f7_31_7674=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1633095\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18809350\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15918746\">",
"      GENERAL APPROACH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18809358\">",
"      MECHANISM OF ARRHYTHMOGENESIS IN PREGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18809366\">",
"      PALPITATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18809374\">",
"      VENTRICULAR PREMATURE BEATS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809382\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809390\">",
"      Management during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18809398\">",
"      EPIDEMIOLOGY OF VT AND VF",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18809414\">",
"      IDIOPATHIC VT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809422\">",
"      Management during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18809430\">",
"      LONG QT SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809438\">",
"      Management during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18807931\">",
"      VT IN WOMEN WITH STRUCTURAL HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809446\">",
"      Hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809454\">",
"      Congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809462\">",
"      Peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18807997\">",
"      MANAGEMENT OF VT DURING PREGNANCY IN WOMEN WITH STRUCTURAL HEART DISEASE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809470\">",
"      Management of acute episodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809478\">",
"      Electrical cardioversion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809486\">",
"      Prophylactic pharmacologic therapy during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809494\">",
"      Implantable cardioverter-defibrillator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18809502\">",
"      Radiofrequency catheter ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18808159\">",
"      ISSUES REGARDING ANTIARRHYTHMIC DRUG TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1633095\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"CARD/13601\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13601|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/11/8382\" title=\"figure 1\">",
"      Prevalence arrhythmias pregnancy congenital heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"CARD/13601|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\" title=\"table 1\">",
"      Drug ratings in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?8/35/8765\" title=\"table 2\">",
"      Antiarrhythmic drugs in pregnancy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/33/13850?source=related_link\">",
"      Advanced cardiac life support (ACLS) in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/19/31034?source=related_link\">",
"      Approach to the diagnosis and treatment of wide QRS complex tachycardias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/35/17977?source=related_link\">",
"      Basic principles and technique of cardioversion and defibrillation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28250?source=related_link\">",
"      Brugada syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/33/23062?source=related_link\">",
"      Cardiovascular effects of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/50/11050?source=related_link\">",
"      Cardioversion for specific arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/52/13129?source=related_link\">",
"      Catheter ablation for ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/10/30890?source=related_link\">",
"      Clinical features and treatment of ventricular arrhythmias during acute myocardial infarction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2202?source=related_link\">",
"      Clinical features of congenital long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/22/32106?source=related_link\">",
"      Clinical manifestations and diagnosis of arrhythmogenic right ventricular cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/36/36424?source=related_link\">",
"      Clinical significance and treatment of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/60/38857?source=related_link\">",
"      Clinical uses of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/29/28120?source=related_link\">",
"      Diagnostic imaging procedures during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/57/1942?source=related_link\">",
"      ECG tutorial: Ventricular arrhythmias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/5/42070?source=related_link\">",
"      Enhanced cardiac automaticity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/44/29383?source=related_link\">",
"      Gestational hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/57/23449?source=related_link\">",
"      Major side effects of amiodarone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/22/20840?source=related_link\">",
"      Management of cardiopulmonary arrest in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/40/20105?source=related_link\">",
"      Maternal cardiovascular and hemodynamic adaptations to pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/14/26858?source=related_link\">",
"      Monomorphic ventricular tachycardia in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/41/13974?source=related_link\">",
"      Nonsustained VT in the absence of apparent structural heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/10/22696?source=related_link\">",
"      Overview of hypertrophic cardiomyopathy management including treatment of special problems",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/11/20665?source=related_link\">",
"      Overview of palpitations in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/890?source=related_link\">",
"      Overview of sudden cardiac arrest and sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/51/16186?source=related_link\">",
"      Overview of thyroid disease in pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/62/18410?source=related_link\">",
"      Peripartum cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/7/29818?source=related_link\">",
"      Pregnancy in women with congenital heart disease: General principles",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/21/35159?source=related_link\">",
"      Pregnancy in women with congenital heart disease: Specific lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/6/9320?source=related_link\">",
"      Prevalence and evaluation of ventricular premature beats",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/23/43385?source=related_link\">",
"      Role of implantable cardioverter-defibrillators for the secondary prevention of sudden cardiac death",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/55/19322?source=related_link\">",
"      Secondary and primary prevention of sudden cardiac death in heart failure and cardiomyopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/45/16085?source=related_link\">",
"      Significance of hypomagnesemia in cardiovascular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/1/14362?source=related_link\">",
"      Supraventricular arrhythmias during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/3/22586?source=related_link\">",
"      Ventricular arrhythmias and sudden cardiac arrest in hypertrophic cardiomyopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_31_7675="Causes panc exocrine insuffic";
var content_f7_31_7675=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F63433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F63433&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Causes of pancreatic exocrine insufficiency",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Chronic pancreatitis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Cystic fibrosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Main pancreas duct obstruction (adenocarcinoma, intraductal papillary mucinous neoplasm, pancreas divisum, etc.)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pancreatic resection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Gastric resection",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short bowel syndrome",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Severe undernutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hereditary hemochromatosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Alpha 1 antitrypsin deficiency",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shwachmann-Diamond-Oski syndrome",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Cleveland Clinic Foundation.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7675=[""].join("\n");
var outline_f7_31_7675=null;
var title_f7_31_7676="Lumbosacral radiculopathy symptoms signs";
var content_f7_31_7676=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F75645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F75645&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Solitary nerve root lesions of the lumbosacral spine",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Root",
"       </td>",
"       <td class=\"subtitle1\">",
"        Pain",
"       </td>",
"       <td class=\"subtitle1\">",
"        Sensory loss",
"       </td>",
"       <td class=\"subtitle1\">",
"        Weakness",
"       </td>",
"       <td class=\"subtitle1\">",
"        Stretch reflex loss",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L1",
"       </td>",
"       <td>",
"        Inguinal region",
"       </td>",
"       <td>",
"        Inguinal region",
"       </td>",
"       <td>",
"        Rarely hip flexion",
"       </td>",
"       <td>",
"        None",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L2-L3-L4",
"       </td>",
"       <td>",
"        Back, radiating into anterior thigh, and at times medial lower leg",
"       </td>",
"       <td>",
"        Anterior thigh, occasionally medial lower leg",
"       </td>",
"       <td>",
"        Hip flexion, hip adduction, knee extension",
"       </td>",
"       <td>",
"        Patellar tendon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        L5",
"       </td>",
"       <td>",
"        Back, radiating into buttock, lateral thigh, lateral calf and dorsum foot, great toe",
"       </td>",
"       <td>",
"        Lateral calf, dorsum foot, web space between first and second toe",
"       </td>",
"       <td>",
"        Hip abduction, knee flexion, foot dorsiflexion, toe extension and flexion, foot inversion and eversion",
"       </td>",
"       <td>",
"        Semitendinosus/semibranosus (internal hamstrings) tendon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S1",
"       </td>",
"       <td>",
"        Back, radiating into buttock, lateral or posterior thigh, posterior calf, lateral or plantar foot",
"       </td>",
"       <td>",
"        Posterior calf, lateral or plantar aspect of foot",
"       </td>",
"       <td>",
"        Hip extension, knee flexion, plantar flexion of the foot",
"       </td>",
"       <td>",
"        Achilles tendon",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S2-S3-S4",
"       </td>",
"       <td>",
"        Sacral or buttock pain radiating into the posterior aspect of the leg or the perineum",
"       </td>",
"       <td>",
"        Medial buttock, perineal, and perianal regions",
"       </td>",
"       <td>",
"        Weakness may be minimal, with urinary and fecal incontinence as well as sexual dysfunction",
"       </td>",
"       <td>",
"        Bulbocavernosus, anal wink",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7676=[""].join("\n");
var outline_f7_31_7676=null;
var title_f7_31_7677="Meta-analyses trials of ESA use addressing cancer outcomes";
var content_f7_31_7677=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F83621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F83621&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Summary of meta-analyses of controlled trials of ESA use in patients with cancer that report disease progression outcomes",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Meta-analysis publication*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Number of trials (number of patients)",
"       </td>",
"       <td class=\"subtitle1\">",
"        Treatment setting",
"       </td>",
"       <td class=\"subtitle1\">",
"        Disease progression statistic",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Seidenfeld J et al, 2006",
"        <sup>",
"         [1]",
"        </sup>",
"       </td>",
"       <td>",
"        5 (688)",
"       </td>",
"       <td>",
"        <p>",
"         3 chemotherapy",
"        </p>",
"        2 radiotherapy only",
"       </td>",
"       <td>",
"        RR for complete response = 1.00 (95% CI: 0.92 - 1.10)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ludwig H et al, 2009",
"        <sup>",
"         [2]",
"        </sup>",
"       </td>",
"       <td>",
"        6 (2122)",
"       </td>",
"       <td>",
"        6 chemotherapy",
"       </td>",
"       <td>",
"        <p>",
"         HR for disease progression = 0.92 (95% CI: 0.82 - 1.03)",
"        </p>",
"        HR for PFS = 0.93 (95% CI: 0.84-1.04)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Aapro M et al, 2009",
"        <sup>",
"         [3]",
"        </sup>",
"       </td>",
"       <td>",
"        12 (2297)",
"       </td>",
"       <td>",
"        <p>",
"         9 chemotherapy",
"        </p>",
"        <p>",
"         2 surgery",
"        </p>",
"        <p>",
"         1 radiotherapy only",
"        </p>",
"       </td>",
"       <td>",
"        HR for disease progression = 0.85 (95% CI: 0.72 - 1.01)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Glaspy J et al, 2010",
"        <sup>",
"         [4]",
"        </sup>",
"       </td>",
"       <td>",
"        26 (9646)",
"       </td>",
"       <td>",
"        <p>",
"         21 chemotherapy",
"        </p>",
"        <p>",
"         1 anemia of cancer",
"        </p>",
"        4 radiotherapy only",
"       </td>",
"       <td>",
"        OR for disease progression = 1.01 (95% CI: 0.90-1.14)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;Tonia T et al, 2012",
"        <sup>",
"         [5]",
"        </sup>",
"       </td>",
"       <td>",
"        15 (5012)",
"       </td>",
"       <td>",
"        Not reported",
"       </td>",
"       <td>",
"        RR &nbsp;for complete response = 1.02 (95% CI: 0.98-1.06)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ESA: erythropoiesis-stimulating agents; PFS: progression-free survival; HR: hazard ratio; CI: confidence interval; RR: relative risk; OR: odds ratio.",
"     <br>",
"      <br>",
"       * These meta-analyses examined 42 studies and included nearly the same studies or a subset of the same studies. Thus, they do not report independent effects based on analyses of completely different data sets.",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     References:",
"     <ol>",
"      <li>",
"       Seidenfeld J, Piper M, Bohlius J, et al.Comparative Effectiveness of Epoetin and Darbepoetin for Managing Anemia in Patients Undergoing Cancer Treatment Comparative Effectiveness Review No. 3. (Prepared by Blue Cross and Blue Shield Association Technology Evaluation Center Evidence-based Practice Center under Contract No. 290-02-0026). Agency for Healthcare Research and Quality: Rockville, MD. May 2006 Available from file:// effectivehealthcare.ahrq.gov/repFiles/EPO%20Final.pdf.",
"      </li>",
"      <li>",
"       Ludwig H, Crawford J, Osterborg A, et al. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol 2009; 27:2838.",
"      </li>",
"      <li>",
"       Aapro M, Osterwalder B, Scherhag A, Burger HU. Epoetin-beta treatment in patients with cancer chemotherapy-induced anaemia: the impact of initial haemoglobin and target haemoglobin levels on survival, tumour progression and thromboembolic events. Br J Cancer 2009; 101:1961.",
"      </li>",
"      <li>",
"       Glaspy J, Crawford J, Vansteenkiste J, et al. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer 2010; 102:301.",
"      </li>",
"      <li>",
"       Tonia T,&nbsp;&nbsp;Mettler A, Robert N, et al. Erythropoietin or darbepoetin for patients with cancer. Cochrane Database Syst Rev 2012; :CD003407.",
"      </li>",
"     </ol>",
"     Adapted by permission from: Macmillan Publishers Ltd on behalf of Cancer Research UK: Aapro M, Jelkmann W, Constantinescu SN, Leyland-Jones B. Effects of erythropoietin receptors and erythropoiesis-stimulating agents on disease progression in cancer. Br J Cancer 2012; 106:1249. file://www.nature.com/bjc/index.html. Copyright &copy; 2012.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7677=[""].join("\n");
var outline_f7_31_7677=null;
var title_f7_31_7678="PCN desens IV pump";
var content_f7_31_7678=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F80213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F80213&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Intravenous desensitization protocol for penicillin, using a continuous infusion pump (example dose of 1000 mg)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Step",
"       </td>",
"       <td class=\"subtitle1\">",
"        Penicillin, mg/mL",
"       </td>",
"       <td class=\"subtitle1\">",
"        Flow rate, mL/hour",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose, mg",
"       </td>",
"       <td class=\"subtitle1\">",
"        Cumulative dose, mg",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0.015",
"       </td>",
"       <td>",
"        0.015",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        0.03",
"       </td>",
"       <td>",
"        0.045",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        0.01",
"       </td>",
"       <td>",
"        24",
"       </td>",
"       <td>",
"        0.06",
"       </td>",
"       <td>",
"        0.105",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.125",
"       </td>",
"       <td>",
"        0.23",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        0.25",
"       </td>",
"       <td>",
"        0.48",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        20",
"       </td>",
"       <td>",
"        0.5",
"       </td>",
"       <td>",
"        1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        7",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        1",
"       </td>",
"       <td>",
"        2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        8",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        2",
"       </td>",
"       <td>",
"        4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        0.1",
"       </td>",
"       <td>",
"        160",
"       </td>",
"       <td>",
"        4",
"       </td>",
"       <td>",
"        8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        3",
"       </td>",
"       <td>",
"        7.5",
"       </td>",
"       <td>",
"        15",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        6",
"       </td>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        30",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        12",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        60",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        13",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        62.5",
"       </td>",
"       <td>",
"        123",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        14",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        50",
"       </td>",
"       <td>",
"        125",
"       </td>",
"       <td>",
"        250",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        15",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        100",
"       </td>",
"       <td>",
"        250",
"       </td>",
"       <td>",
"        500",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        16",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        200",
"       </td>",
"       <td>",
"        500",
"       </td>",
"       <td>",
"        1000",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         NOTE:",
"        </strong>",
"        Three solutions of penicillin are required: 0.01 mg/mL, 0.1 mg/mL, and 10 mg/mL. Each step is administered over 15 minutes. At conclusion of protocol, observe patient for 30 minutes, then give any remaining amount required to reach a full therapeutic dose by the desired route.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        Total time = 4+ hours.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Desensitization protocol instructions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        1. Confirm written consent is in medical record.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        2. Please ensure preceding dose of beta-blockers was held, unless otherwise advised by supervising clinician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        3. Obtain IV access, and vital signs (temperature, HR, BP, RR, oxygen saturation, peak flow).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        4. Have at bedside: Epinephrine 0.3 mg (for adult) for IM injection, oxygen, normal saline, peak flow meter, and BP cuff, albulterol, injectable preparation of diphenhydramine , and methylprednisolone.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        5. A nurse must closely observe the patient throughout the protocol (one-to-one).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"5\">",
"        <strong>",
"         Administration:",
"        </strong>",
"        Hang each solution successively. Each step is administered over 15 minutes, per protocol. There is no reason to wait between bags. Vital signs should be taken and recorded every 15 minutes, and every 30 minutes during the last step.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Monitoring and charting during desensitization:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        Please clearly document any reaction, including:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"5\">",
"        a. Patient's symptoms, vital signs, and physical findings;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"5\">",
"        b. Exactly when the reaction occurred (ie, what step, how many minutes into that step);",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\" colspan=\"5\">",
"        c. Treatment administered, how and when the reaction resolved, and when the protocol was restarted.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle2_left\" colspan=\"5\">",
"        Treatment of allergic reactions:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        1.",
"        <strong>",
"         For mild reactions:",
"        </strong>",
"        In case of isolated itching, flushing, hives, mild chest tightness, nausea, abdominal pain, or back pain, with normal vital signs, stop the infusion and treat with IV diphenhydramine. Observe patient until the reaction subsides, and then resume the protocol by repeating the step at which the reaction occurred.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        2.",
"        <strong>",
"         For severe reactions:",
"        </strong>",
"        In case of hypotension, throat swelling, wheezing/respiratory distress, or decreased oxygen saturation, stop the infusion and treat with epinephrine 0.3 mg IM x 1, diphenhydramine and methylprednisolone IV, oxygen, inhaled albuterol for bronchospasm, and IV fluids (normal saline). Place patient in a recumbent position if hypotensive. Consider glucagon 1 to 2 mg IV bolus if patient has taken beta-blockers, followed by infusion at 1 to 5 mg/hour.",
"        <strong>",
"         Immediately alert the housestaff and supervising clinician.",
"        </strong>",
"        When the patient is stable, the protocol will be resumed as instructed by the supervising clinician.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\" colspan=\"5\">",
"        <strong>",
"         Contact the supervising clinician for ANY severe or prolonged reaction, or any questions regarding the protocol, reactions, and appropriate management.",
"        </strong>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Protocol courtesy of Roland Solensky, MD.",
"     <br>",
"      Directions for administration courtesy of Mariana Castells, MD, PhD",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7678=[""].join("\n");
var outline_f7_31_7678=null;
var title_f7_31_7679="Paratracheal mass MRI II";
var content_f7_31_7679=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F56669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F56669&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Paratracheal mass due to primary lung adenocarcinoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 265px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Axial T1-weighted section demonstrates a right paratracheal mass. There are irregular margins with the lung parenchyma, consistent with either a pulmonary primary tumor or invasion of lung by a mediastinal tumor.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Stark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_31_7679=[""].join("\n");
var outline_f7_31_7679=null;
